 
Document Type:  Study protocol 
Official Title:  A randomized, double-blind, parallel group, placebo-controlled, 
multi-center study to assess the safety and tolerability of monthly subcutaneous administrations of a low and high dose cohort of osocimab to ESRD patients on regular hemodialysis 
Study ID: [REMOVED] 
Document Date:  16-M ar-2020 
 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  1of 77
Title Page
Protocol Title: 
A randomized, double -blind, parallel group, placebo -controlled , multi -center study to assess 
the safet y and tolerability of monthly  subcutaneous administrations of a low and high dose
cohort of osocimab to ESRD patients onregular hemodialy sis
Protocol Number: 20115
Compound Number: BAY 1213790 / Osocimab
Study Phase: Phase 2b
Short Title: Osocimab in ESRD Phase 2b study
Acronym: CONVERT
Sponso r Name: Bayer AG
Legal Registered Address:
Non-US: Bay er AG, 51368 L everkusen, Germany 
US territory : Bay er HealthCare Pharmaceuticals Inc., 100 Bay er Boulevard, P.O. Box 915, 
Whippany  NJ 07981
-0915, USA
Regulatory Agency Identifier Number(s):
IND:141027
EudraCT: 2019-003957-27
Approval Date: 16MAR 2020
Confidential
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not 
associated with the clinic
al investigation or its use for any other purpose w ithout the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names withou t these symbols does not imply that these names are not protected.
CONFIDENTIAL 
Sponsor Signatory 
 M 
Global Clinical Lead Clinical Study Protocol 
No. BAY 1213790 / 20115 
Vers ion 1.0 
Date 
Medical Monitor name and contact information will be provided separately . Page: 2 of77 
PPD
PPD
PPD
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 3of 77
Table of Contents
Title Page ................................................................................................................................... 1
Sponsor Signatory .................................................................................................................... 2
Table of Contents ..................................................................................................................... 3
Table of Tables ......................................................................................................................... 5
Table of Figures
........................................................................................................................ 5
1.Protocol Summary ............................................................................................................ 6
1.1 Synopsis ........................................................................................................................... 6
1.2 Schema ............................................................................................................................. 8
1.3
Schedule of Activities (SoA) ........................................................................................... 9
2.
Introduction ..................................................................................................................... 17
2.1 Study  Rationale .............................................................................................................. 17
2.2 Background .................................................................................................................... 17
2.2.1 Cardiovascular Disease in ESRD Patients .................................................................. 17
2.2.2 Cardiovascular Treatment Options for ESRD Patients .............................................. 18
2.2.3 Factor XI ..................................................................................................................... 18
2.2.4 Osocimab (BA Y 1213790) ......................................................................................... 18
2.2.4.1 Preclinical Data ....................................................................................................... 18
2.2.4.2 Human Experience .................................................................................................. 19
2.2.4.3 Rationale for the Development of Osocimab in ESRD Patients .............................
20
2.3 Benefit/Risk Assessment ............................................................................................... 20
2.3.1 Risk Assessment ......................................................................................................... 21
2.3.2 Benefit Assessment .................................................................................................... 22
2.3.3
Overall Benefit: Risk Conclusion............................................................................... 22
3.Objectives and Endpoints ............................................................................................... 23
4.Study Design .................................................................................................................... 24
4.1 Overall Design ............................................................................................................... 24
4.2 Scientific Rationale for Study  Design ........................................................................... 25
4.3 Justification for Dose ..................................................................................................... 26
4.4 End of Study  Definition ................................................................................................. 27
5.Study Population ............................................................................................................. 27
5.1 Inclusion Criteria
........................................................................................................... 27
5.2 Exclusion Criteria .......................................................................................................... 28
5.3 Lifesty le Considerations ................................................................................................ 29
5.4 Screen Failures ............................................................................................................... 29
6.Study Intervention .......................................................................................................... 29
6.1 Study  Interventions Administered ................................................................................. 29
6.2 Preparation/Handling/Storage/Accountability ............................................................... 31
6.3
Measures to Minimize Bias: Randomization and Blinding ........................................... 31
6.4 Study  Intervention Compliance ..................................................................................... 32
6.5 Concomitant Therap y
.................................................................................................... 32
6.6 Dose M odification ......................................................................................................... 33
6.7 Intervention after the End of the Study .......................................................................... 33
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 4of 77
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .......................................................................................... 34
7.1 Discontinuation of Study I ntervention ........................................................................... 34
7.1.1 Temporary  Discontinuation ........................................................................................ 35
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... 35
7.3 Lost to Follow Up .......................................................................................................... 36
8.Study Assessments and Procedures ............................................................................... 36
8.1 Efficacy  Assessments .................................................................................................... 37
8.2 Safety Assessments ........................................................................................................ 37
8.2.1 Main Safet y Assessment ............................................................................................. 38
8.2.2 Bleeding Events .......................................................................................................... 38
8.2.2.1
Assessment of AV Access Bleeding ....................................................................... 39
8.2.2.2 Recommendations for Bleeding and Surgery  Management .................................... 39
8.2.3 Physical Examinations ................................................................................................ 41
8.2.4 Vital Signs .................................................................................................................. 41
8.2.5 Electrocardiograms ..................................................................................................... 41
8.2.6 Clinical Safety  Laboratory  Assessments .................................................................... 42
8.2.7 Dialy sis Information ................................................................................................... 42
8.2.7.1 Renal Replacement Therapy  (RRT) Baseline Information (General Dial ysis 
Information) ............................................................................................................ 42
8.2.7.2 Dialy sis Prescription Changes ................................................................................. 43
8.3
Adverse Events and Serious Adverse Events ................................................................ 43
8.3.1 Time Period and Frequency  for Collecting AE and SAE I nformation .......................
43
8.3.2 Method of Detecting AEs and SAEs .......................................................................... 43
8.3.3 Follow -up of AEs and SAEs ...................................................................................... 43
8.3.4 Regulatory  Reporting Requirements for SAEs ................................ .......................... 43
8.3.5 Pregnancy ................................................................................................................... 45
8.3.6
Cardiovascular and Death Events............................................................................... 45
8.3.7 Disease -Related Events and/or Disease -Related Outcomes Not Qualify ing as AEs 
or SAEs ................................ ................................ ................................ ....................... 45
8.3.8 Adverse Events of Special Interest ............................................................................. 45
8.3.8.1
Stopping Rule for Stud y Drug Administration in Case of Thrombocy topenia ....... 46
8.3.8.2 Hypersensitivity  Reactions ...................................................................................... 46
8.3.9 AEs Requiring Submission to the CI AC.................................................................... 48
8.4 Treatment of Overdose .................................................................................................. 48
8.5 Pharmacokinetics ........................................................................................................... 48
8.6 Pharmacod ynamics ........................................................................................................ 49
8.7 Genetics ......................................................................................................................... 50
8.8 Biomarkers ..................................................................................................................... 50
8.9 Immunogenicit
y Assessments ........................................................................................ 50
8.10
Health Economics OR Medical Resource Utilization and Health Economics .............. 51
9. Statistical Considera tions ............................................................................................... 51
9.1 Statistical Hy potheses .................................................................................................... 51
9.2 Sample Size Determination ........................................................................................... 51
9.3 Populations for Analy ses............................................................................................... 52
9.4 Statistical Analy ses........................................................................................................ 52
9.4.1 General 
Considerations............................................................................................... 52
9.4.2 Primary  Endpoints ...................................................................................................... 53
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 5of 77
9.4.3 Secondary  Endpoints ................................ ................................ ................................ .. 54
9.4.4 Other Anal yses........................................................................................................... 54
9.5 Interim Anal yses............................................................................................................ 55
9.6 Data Monitoring Committee (DMC) ............................................................................. 55
10.
Supporting Documentation and Operational Considerations .................................... 56
10.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................
56
10.1.1 Regulatory  and Ethical Considerations ...................................................................... 56
10.1.2 Financial Disclosure ................................................................................................... 56
10.1.3 Informed Consent Process .......................................................................................... 57
10.1.4 Data Protection ........................................................................................................... 57
10.1.5 Committees Structure ................................................................................................. 58
10.1.6 Dissemination of Clinical Study  Data ........................................................................ 58
10.1.7 Data Qualit y Assurance .............................................................................................. 58
10.1.8 Source Documents ...................................................................................................... 59
10.1.9 Study  and Site Start and Closure ................................................................................ 59
10.1.10 Publication Policy ....................................................................................................... 60
10.2 Appendix 2: Clinical L aboratory  Tests .......................................................................... 60
10.3
Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .............................................................................................. 63
10.3.1 Definition of AE ......................................................................................................... 63
10.3.2 Def
inition of SAE ....................................................................................................... 64
10.3.3
Recording and Follow-Up of AE and/or SAE............................................................ 65
10.3.4 Reporting of SAEs ...................................................................................................... 68
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy  Information .........
68
10.5 Appendix 5: Genetics..................................................................................................... 71
10.6 Appendix 6: Country -specific Requirements ................................................................ 71
10.7
Appendix 7: Abbreviations and Definitions .................................................................. 72
11.References ........................................................................................................................ 75
Table of Tables
Table 1
–1: Schedule of Activities: Main Treatment Period ................................ ..................... 10
Table 1–2: Schedule of Activities – Extension Treatment Period and Follow -up Period ....... 14
Table 2–1: Risk Assessment for Osocimab .............................................................................. 21
Table 3
–1: Objectives and Endpoints ....................................................................................... 23
Table 6
–1: Study  Interventions ................................................................................................ 30
Table 8
–1: Common Terminology  for Adverse Events Related to I mmune Sy stem Disorders 
(CTCAE v-5.0)...................................................................................................... 47
Table 9–1: Populations for Anal yses....................................................................................... 52
Table 10
–1: Protocol -required Laboratory  Assessments ......................................................... 62
Table of Figures
Figure 1 –1: Study  Design Overv iew................................ ................................ .......................... 8
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 6of 77
1. Protocol Summary
1.1 Synopsis
Protocol Title: A randomized, double -blind, parallel group, placebo -controlled, multi- center 
study to assess the safet y and tolerability  of monthly  subcutaneous administrations of a low 
and high dose 
cohort of osocimab to ESRD patient s on regular hemodialy sis
Short Title: Osocimab in ESRD Phase 2b study
Rationale: It is well known that end-stage renal disease (ESRD )patients on dialy sis are at 
high risk for cardiovascular diseases. By  targeting FXI, osocimab has the potential to provide 
an efficacious treatment for the prevention of thromboembolic events like myocardial 
infarction ( MI), stroke and cardiovascular deat
h with a favorable risk profile for unwanted 
bleeding. This Phase 2b trial will assess the safet y and characterize the
pharmacokinetic/pharmacody namic ( PK/PD ) profile of two different dose cohorts of 
osocimab given subcutaneously  once a month to p articipants with ESRD.  
Objec tives and Endpoints:
Objectives Endpoints
Primary
To clinically assess the safety of different 
doses of osocimab administered 
subcutaneously once a month during main
treatment p eriod as compared to placeboComposite of major and clinically -relevant 
non-major bleeding events ( in alignment with
ISTH guideline s), as assessed by blinded 
Central Independent Adjudication Committee 
(CIAC)
Composite of moderate and severe AEs and 
SAEs
Secondary
To assess the change of key PD parameter 
from baselineActivated partial t hromboplastin time (aPTT ), 
FXIa activity at trough levels after 6 months
Overall Design
Disclosure Statement: This is a covariate -adaptive randomized , double -blind, parallel group, 
placebo controlled, multi -center study with 2 cohorts of osocimab (lowand high dose) tested 
against placebo in ESRD patients on hemodialy sis.In this protocol, the term hemodialy sis 
includes hemodiafiltration .
Sponsor, participant sand investigator s are being blinded with 
respect to active treatment versus matching placebo , but not blinded to dose cohort (low or 
high dose) . 
A Data Monitoring Committee will regularly  review the safet y data of the partic ipants.
Intervention Model: Parallel 
Primary Purpose: Treatment
Number of Arms: 2 dose cohorts , 3 groups, 4 arms
Blinding :Participants, Investigator, Outcome As sessor
Number of Participants: Approximately 600randomized
Approximately  600 participants (up to 
750) will be randoml y assigned to study  intervention
such that approximately  555 participants complete the main treatment period . 
For details on s ample size determination see Section 9.2.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 7of 77
Intervention Groups and Du ration:
The following stud y interventions will be administered in the stud y:
Osocimab (BAY 1213790): sponsor’ s study  drug under investigation
Placebo to osocimab
Different doses will be achieved b y administering a different volume. 
Low dose cohort
105mgsingle loading dose as subcutaneous abdominal injection at visit 5, followed 
by monthly  (i.e. 30 day s ± 3 day s) maintenance doses of 52.5 mg starting at visit 8
until the end of the extension treatment period . Placebo will be administered 
subcutaneousl y in the same manner as osocimab.
High dose cohort:
210 mg single loading dose as subcutaneous abdominal injection at visit 5, followed 
by monthly  (i.e. 30 day s ± 3 day s) maintenance doses of 105 mg starting at visit 8
until the end of the extension treatment period
. Placebo will be administered 
subcutaneousl y in the same manner as osocimab.
The two dose cohorts (lowdose and high dose ) follow the same treatment schedule:
Screening p eriod (visit 1) : up to 14 days 
Randomization (visit 2) : 1 day
Pre-treatment p eriod ( from visit 2until visit 4) : 7 day s
Main treatment 
period ( from visit 5 until EOMT visit) : 6 months
Extension treatment period ( from visit 19 until EOET visit) : up to 12 months
Follow -up period ( from visit 32 until visit 35 ): 4 months after end of treatment 
(EOMT or EOET)
The mandatory extension 
treatment period is continued until the last study  participant has 
completed its 6 months m ain treatment period or to a maximum of 18 months ( i.e. 6 months 
main treatment period + 12 months extension treatme nt period). When the last participant has 
completed its6 months 
main treatment period including EOMT (end of main treatment 
period) visit, all participants who are in extension treatment period at this time point will not 
receive an y further dosing and will participate in an EOET (end of extension treatment 
period) visit at the next regular monthly  extension visit andwill move to the follow -up period. 
The last participant of the whole stud y will not take part in the extension treatment 
period. 
Data Mon itoring Committee: Yes
The study  will be overseen by a Steering Committee (SC), a Data Monitoring Committee 
(DMC) and 
a Central Independent Adjudication Committee (CI AC).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page: 8of 77
1.2 Schema
Figure 1–1: Study Design Overview
Abbreviations: EOET =end of extension treatment period , EOMT =end of main treatment period , LD =loading 
dose, MD =maintenance/ monthly dose , pts =participants, R =randomization, V =visit
Further details on the randomization schema can be found in Section 6.3.
The follow -upperiod ends 5 months after last study intervention and 4 months after EOMT or EOET .
I Study I interven tion Dose [mg] Pre-treatmen t I 
period Main treatment period I Extension treatment period 
osocimab 200 pis -----+ : -------- ----------------- ------• Low dose I LO 105 mg : Post 
cohort MD52 .5mg : treatment placebo 100 pis ------------------ ------------- • : follow-up Screening {E1 : period period s : osocimab 200 pis -----+ ------------------ ------------- • High dose I LD210mg 
cohort MD 105 mg 
placebo 100 pis -----+ ' -------------------------------• 
creening 2 week Randomization 1 week > ~ __ 6 _m _on_t _ h_ s_~ >I~' __ u _ p _t _ o _ 1_ 2_ m _o _n _ t_ hs _~ 4 month s 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  9of 77
1.3 Schedule of Activities (SoA)
Visit procedures must be completed on a single day, except screening period.
Please note that if screening parameters are available as part of routine medical practice, these are not required to be repe ated as long as they  
were measured within 14 day s of screening and meet the thresholds defined in the in -/exclusion criteria.
It is not allowed to perform dialy ses which are linked to study  visits outside of the study  center. Participants should come to the same dial ysis 
center for each visit. Visits in between dial yses, i.e.not linked to a study  visit, can be performed outside of the study  center. 
PDandbiomarker sampling and anal yses are mandatory  for all participants except China and have to be done according to the SoA .
Please refer to Table 1–1for the Schedule of Activities of the main treatment period and to Table 1–2for the Sche dule of Activities of the 
extension treatment period and the follow -up period.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  10of 77
Table 1–1: Schedule of Activities: Main Treatment P eriod
Study  period
(Duration)Pre-treatment 
period
(7 days)Main treatment periodd
(6 months)Notes
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18EOMTb
EDa
Study  intervention
LD or MD
SCRc
RNDLD MD MD MD MD MD
Day Day since last study  intervention dose
-13 
to 11 3 6 8 2 4 30 2 4 30 4 30 4 30 4 30 4 30
Approx. month - 1 1 1 1 1 1 2 2 2 3 3 4 4 5 5 6 6 7
Window (days) +3 +3 +3 + 3 + 3 ± 3 +3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3Adeviation of 2-3 days 
equals 1 dialysis 
session. Section 7.1.
Initiation procedures
Informed consent ●Signed written informed 
consent must be 
available before any 
study procedures are 
conducted.
In/ Exclusion criteria ● ●
Demography ●
Randomization via 
IWRS●
Clinical procedures / assessments
Complete physical 
examination● ●
Height, dry body 
weight●
Vital signs ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●Pre-dialysis. See 
Section 8.2.4 .
12-lead ECG ● ● ● ● ●Pre-dialysis . See 
Section 8.2.5 .
Prior and 
concomitant 
medication--------------------------------------------------------------   Continuous reporting  ----------------------------------------------------- -------------- >
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  11of 77
Table 1–1: Schedule of Activities: Main Treatment P eriod
Study  period
(Duration)Pre-treatment 
period
(7 days)Main treatment periodd
(6 months)Notes
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18EOMTb
EDa
Study  intervention
LD or MD
SCRc
RNDLD MD MD MD MD MD
Day Day since last study  intervention dose
-13 
to 11 3 6 8 2 4 30 2 4 30 4 30 4 30 4 30 4 30
Approx. month - 1 1 1 1 1 1 2 2 2 3 3 4 4 5 5 6 6 7
Window (days) +3 +3 +3 + 3 + 3 ± 3 +3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3Adeviation of 2-3 days 
equals 1 dialysis 
session. Section 7.1.
Medical history ●The start of dialysis 
(dialysis vintage) and 
the start of use of the 
current vascular access 
should be documented.
AE/SAE/AESI --------------------------------------------------------------   Continuous reporting  ------------------------------------------------------------------- >
Heparin dose data 
collection● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Hemodialysis data 
collection (including 
pre-/post -dialysis 
weight, online Kt/V)● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●The term hemodialysis 
includes 
hemodiafiltration. Online 
Kt/V if provided by the 
dialysis machine.
AV access bleeding 
assessment● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●Not applicable for 
catheter dialysis 
access.
SQCS assessment ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Study  intervention
Study intervention 
administered● ● ● ● ● ●Administered sc 
abdominally within one 
hour prior to dialysis.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  12of 77
Table 1–1: Schedule of Activities: Main Treatment P eriod
Study  period
(Duration)Pre-treatment 
period
(7 days)Main treatment periodd
(6 months)Notes
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18EOMTb
EDa
Study  intervention
LD or MD
SCRc
RNDLD MD MD MD MD MD
Day Day since last study  intervention dose
-13 
to 11 3 6 8 2 4 30 2 4 30 4 30 4 30 4 30 4 30
Approx. month - 1 1 1 1 1 1 2 2 2 3 3 4 4 5 5 6 6 7
Window (days) +3 +3 +3 + 3 + 3 ± 3 +3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3Adeviation of 2-3 days 
equals 1 dialysis 
session. Section 7.1.
Laboratory  assessmentLocal 
laboratorySerum 
pregnancy test ● ●See Section 10.2.
Screening 
tests●See Section 8.2.6 and 
Section 10.2.Central laboratoryLaboratory 
calculated 
URR and Kt/V● ● ● ● ●For BUN a post -dialysis 
sample needs to be 
taken (central lab). 
Local lab values of URR 
and Kt/V ± 7 days are 
accepted. 
Hematology, 
chemistry, 
coagulation 
and serum 
pregnancy● ● ● ● ● ● ● ●Pre-dialysis. Prior to 
study intervention.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  13of 77
Table 1–1: Schedule of Activities: Main Treatment P eriod
Study  period
(Duration)Pre-treatment 
period
(7 days)Main treatment periodd
(6 months)Notes
Visit number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18EOMTb
EDa
Study  intervention
LD or MD
SCRc
RNDLD MD MD MD MD MD
Day Day since last study  intervention dose
-13 
to 11 3 6 8 2 4 30 2 4 30 4 30 4 30 4 30 4 30
Approx. month - 1 1 1 1 1 1 2 2 2 3 3 4 4 5 5 6 6 7
Window (days) +3 +3 +3 + 3 + 3 ± 3 +3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3 + 3 ± 3Adeviation of 2-3 days 
equals 1 dialysis 
session. Section 7.1.Central laboratoryBiomarker 
geneticse(if 
applicable)●
Biomarkere: 
FVIII, FIX, 
FXII, v WF 
antigen, v WF 
activity●
Pre-dialysis. Prior to 
study intervention.Biomarkerse● ● ● ●
Main PDe
samples● ● ● ● ● ● ● ● ●
Additional PDe
samples ● ●
PK samples ● ● ● ● ● ● ● ● ●
ADA/NAB ● ● ● ●
Abbreviations: ADA =anti-drug antibodies, AE=adverse event, AESI =adverse event of special interest, Approx. =approximately, AV=arteriovenous , BUN =blood urea 
nitrogen, ECG =electrocardiogram, ED = early discontinuation visit, EOET = end of extension treatment period visit, EOMT =end of main treatment period visit,
IWRS=interactive web response system, Kt/V – K = dialyzer urea clearance, t = dialysis time, V = total volume of distribution of urea ,LD=loading dose, MD =maintenance/ 
monthly dose, NAB =neutralizing antibodies, PD =pharmacodynamic, PK = pharmacokinetic, RND = randomization, SAE =serious adverse event, sc=subcutaneous, 
SCR =screening, SQCS =semi -quantitative clotting score, URR =urea reduction ratio
a. It is recommended to perform the ED visit approximately 1 month after last study intervention. After ED the participant moves directly to the follow -up period.
b. EOMT and visit19will be performed at the same day. Both of them are mandatory separate visits and shouldn´t be missed.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  14of 77
c. Screening period covers up to 14 days ( From Day -13 until Day +1). No Day 0 will occur.
d. When the last participant completes his 6 months m ain treatment period including EOMT v isit, all participants who are in the extension treatment p eriod at this time 
point will not receive any further dosing and will participate in an EOET visit at the next regular monthly extension visit. They will move to the follow -up period.
e. Study participating sites in China are excluded from allPDand biomarker sampling and analys es.
Table 1–2: Schedule of Activities –Extension Treatment Period and Follow -up Period
Study  period
(Duration)Extension treatment period
(up to 12 months)Follow -up period
(For 4 months after 
EOMT or EOET)Notes
Visit number 19b20 21 22 23 24 25 26 27 28 29 3031/
EOET 
EDa32 33 34 35
Study  intervention
MDMD MD MD MD MD MD MD MD MD MD MD MD
Day since last study  
intervention dose30 30 30 30 30 30 30 30 30 30 30 30 30 60 90 120 150
Approx. month 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Window (days) ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 5 ± 5 ± 5 ± 5A deviation of 2 -3 days equals 
1 dialysis session. Section 
7.1.
Clinical procedures / assessments
Complete physical 
examination● ● ● ●
Vital signs ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●Pre-dialysis. See Section 
8.2.4 .
12-lead ECG ● ● ● ● ● ●Pre-dialysis. See Section 
8.2.5 .
Concomitant 
medication---------------------------------------------------------   Continuous reporting  ------------------------------------------------------------ >
AE/SAE/AESI ---------------------------------------------------------   Continuous reporting  ------------------------------------------------------------ >
Heparin dose data 
collection● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
Hemodialysis data 
collection (including 
pre-/post dialysis 
weight, online Kt/V)● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●The term hemodialysis 
includes hemodiafiltration.
Online Kt/V if provided by the 
dialysis machine.
AV access bleeding 
assessment● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●Not applicable for catheter 
dialysis access.
SQCS assessment ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ● ●
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  15of 77
Table 1–2: Schedule of Activities –Extension Treatment Period and Follow -up Period
Study  period
(Duration)Extension treatment period
(up to 12 months)Follow -up period
(For 4 months after 
EOMT or EOET)Notes
Visit number 19b20 21 22 23 24 25 26 27 28 29 3031/
EOET 
EDa32 33 34 35
Study  intervention
MDMD MD MD MD MD MD MD MD MD MD MD MD
Day since last study  
intervention dose30 30 30 30 30 30 30 30 30 30 30 30 30 60 90 120 150
Approx. month 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
Window (days) ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 3 ± 5 ± 5 ± 5 ± 5A deviation of 2 -3 days equals 
1 dialysis session. Section 
7.1.
Study  intervention
Study intervention 
administered● ● ● ● ● ● ● ● ● ● ● ●Administered sc abdominally 
within one hour prior to 
dialysis.
Laboratory  AssessmentCentral laboratoryLaboratory 
calculated URR 
and Kt/V● ● ● ●For BUN a post -dialysis 
sample needs to be taken 
(central lab). Local lab values 
of URR and Kt/V ± 7 days are 
accepted.
Hematology, 
chemistry, 
coagulation and 
serum 
pregnancy● ● ● ● ●Pre-dialysis. Prior to study 
intervention.
Biomarkersd●c●c
Pre-dialysis. Prior to study 
intervention.Main PDd
samples ●c●c●e● ●e●
PK samples ●c●c●e● ●e●
ADA/NAB ●c●c●e● ●e●
Abbreviations: ADA =anti-drug antibodies, AE = adverse event, AESI = adverse event of special interest, Approx. = approximately, AV=arteriovenous , BUN = blood urea 
nitrogen ,ECG =electrocardiogram, ED = early discontinuation visit, EOET = end of extension treatment period visit, EOMT =end of main treatment period visit, IWRS = 
interactive web response system ,Kt/V –K = dialyzer urea clearance, t = dialysis time, V = total volume of distribution of urea ,MD=maintenance/ monthly dose, 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  16of 77
NAB = neutralizing antibodies, PD = pharmacodynamic, PK =pharmacokinetic, sc=subcutaneous, SQCS =semi -quantitative clotting score , URR = urea reduction ratio
a. It is recommended to perform t he ED visit approximately 1 month after last study intervention. After ED the participant moves directly to the follow -up period.
b. EOMT and visit 19 will be at the same day. Both of them are mandatory separate visits and shouldn´t be missed.
c. Samples are tak en prior to study intervention at visit 2 7or EOET /ED, whichever comes first.
d. Study participating sites in China are excluded from all PD andbiomarker sampling and analys es.
e. Samples need tobe take n only if no sampling was done approximately 30 days before at a prior visit .
CONFIDENTIAL Clinical Study Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  17of 77
2. Introduction
Osocimab is a novellong-actinganticoagulanttargeting the activated form of FXI with the 
potential to exhibitlower risk of bleeding events than currently available anticoagulants. 
2.1 Study Rationale
It is well known that ESRD patients on dialysis are at high risk for cardiovascular diseases. By targetingFXI, osocimab has the potential to provide an efficacious treatment for the prevention of thromboembolic events like MI, stroke and cardiovascular death with a favorable risk profile for unwanted bleeding. This Phase 2b trial will assess the safety and characterize the PK/PD profile of two different dosecohortsof osocimab given subcutaneously once a month to participantswith ESRD.  
2.2 Background
2.2.1 Cardiovascular Disease in ESRD Patients
Cardiovascular disease is the leading cause of death in adults around the world. World Health 
Organization (WHO) data show that an estimated 17.7 million people died from cardiovascular disease in 2015, which represents 31% of all deaths worldwide. Of these deaths, an estimated 6.7 million were due to stroke and 7.4 million were due to coronary heart disease (1).
It is well known that patients with ESRD have very high cardiovascular morbidity and 
mortality rates. Cardiovascular disease (e.g., coronary artery disease [CAD] and acute coronary syndrome,arrhythmia, chronic heart failure, cerebrovascular events [i.e., stroke]) is the leading cause of death in ESRD patients and accounts for 53% of all deaths with a known cause in patients on hemodialysis ( 2). In a large prospective United States–based study, the 5-
year survival rate for hemodialysis patients was only 40%, with 40% of the deaths being cardiac (3). The annual cardiovascular mortality in the general population increases with age, 
rising from 0.01% in 30-year-old patients to 0.1% in 80-year-old patients ( 4). In contrast, 
there is only a modest age-related increasein cardiovascular mortality in hemodialysis patients, and the annual cardiovascular mortality in a 40-year-old hemodialysis patient is comparable with the mortality observed in an 80-year-old individual in the general population.
CAD incidence among patients initiating hemodialysis is up to 38%, with a relative risk that 
is 5 to 20fold higher than that in the general population. The uremic environment due to the underlying renal disease may accelerate the progression of atherosclerosis and may influence the prevalence of CAD ( 5). Similarly, ESRD itself is seen as a risk factor for 
peripheral artery disease (PAD) as an additional expression of the underlying atherothrombosis/atherosclerosis, which often leads to complications such as non-healing ulcers and lower limb amputation ( 6-7).
High levels of Creactive protein and pro-inflammatory cytokines have been reported in 
patients with ESRD, as well as endothelial dysfunction and increased oxidative stress, which are exacerbated in the setting of ESRD. Atherosclerosis and subsequent atherothrombosis are the drivers of CAD and PAD. These are inflammatory processes and the pro-inflammatory environment in patients with ESRD predisposes them to accelerated plaque formation and rupture, which contributes to thromboembolic events such as acute coronary syndrome/MI,strokeand cardiovascular death. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  18of 77
2.2.2 Cardiovascular Treatment Options for ESRD Patients
Treating patients with ESRD is challenging owing to competing mortalit y risks. Patients with 
chronic kidney  disease (CKD) and ESRD are at an increased risk for both thromboembolic 
events and bleeding (8)and treatment opti ons need to be carefull y evaluated against their 
benefits and risks. Furthermore, the relative benefit
-risk profile of anticoagulation in ESRD 
patients is different from that in patients with normal kidney  function. In the non- ESRD 
population, current anticoagulation therapies have been shown to be efficacious for 
prevention of thromboembolic events (9-11) . However, their use is associated with a variable 
bleeding risk and ESRD patients have a much higher risk for severe bleeding events than the 
non-ESRD population (12). 
Although there are numerous high -quality  randomized clinical trials (RCTs) supporting 
therapeutic cardiovascular interventions in the general population (13), the vast majority  of 
these studies specifically  excluded patients with severe renal impairment. In contrast, very  
few RCTs have evaluated cardiovascular therapies in hemodialy sis. Because of the paucity  of 
RCTs in hemodialy sis patients, most cardiov
ascular therapies in this population are based on 
observational studies or results extrapolated from studies that excluded hemodialy sis patients. 
Hence, due to the much higher bleeding risk of ESRD patients and the unproven benefits of 
anticoagulation ther apy in these patients, most hemodialy sis patients are not treated with 
respect to the prevention of thromboembolic events. 
2.2.3 Factor XI
Factor XI (FXI) is a new target for anticoagulants that have the potential to be associated with 
a lower risk of bleeding events than currently  available anticoagulants. The identification of 
FXI as a safer target is supported b y epidemiological data, stud ies in FXI deficient mice, 
studies with FXI knockdown or inhibition, and animal bleeding models (14).
The formation and the stability  of clots are enhanced by  FXI in in- vitro experiments ( 15-16). 
Furthermore, FXI amplifies thrombin gener ation when coagulation is initiated by  low levels 
of tissue factor (TF) or thrombin. FXI -dependent amplification of thrombin generation also 
leads to activation of thrombin
-activatable fibrinolysis inhibitor, which renders clots resistant 
to fibrinoly sis. Therefore, FXI inhibitors might also indirectly  enhance clot dissolution.
The most solid evidence in support of FXI as a potential therapeutic target came from 
epidemiological data. Observational studies in patients with congenital factor XI deficiency 
suggest edthat these patients are at reduced risk of ischemic stroke, m yocardial infarction, and 
venous thromboembolism (VTE) compared with those with normal factor XI levels (14-19 ) . 
Furthermore, a second -generation antisense oligonucleotide (ASO) that specificall y reduces 
FXI levels (ISIS 416858) y ielded promising results when compared with enoxaparin for 
thromboprophy laxis in patients undergoing elective total knee arthroplast y (TKA) (20). 
2.2.4 Osocimab (BAY 1213790)
Osocimab is a fully  human monoclonal immunoglobulin G1 (IgG1) antibody  that binds 
specificall y to activated factor XIa (FXIa) (21)and exhibits a terminal half-life in plasma
ranging from approximately  30 to 44 day safter intravenous administration.
2.2.4.1 Preclinical Data
Preclinical pharmacology experiments indicated a profound anti thrombotic effect, both in 
arterial and in venous thrombosis models, in the absence of significantly  prolonged bleeding 
times or increased blood loss. I n line with the mechanism of action, the activated partial 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  19of 77
thromboplastin time (aPTT) increased in a dos e-dependent manner and in parallel with the 
antithrombotic effect. Osocimab had no effect on the prothrombin time (PT), confirming that 
the effects of Osocimab were limited to the intrinsic pathway  of coagulation.
As with any  protein product, Osocimab may  induce immune responses affecting safet y and 
product efficacy
. However, the compound is a fully  human monoclonal IgG1 antibody  that 
has been optimized for affinity  and low immunogenicity . The immunogenic potential of 
Osocimab was tested in silico and showed a favorable overall score, similar to other marketed 
monoclonal antibodies. Furthermore, toxicological studies have not identified relevant 
hypersensitivity  effects in Cy nomolgus monkey s after intravenous ( iv)or subcutaneous ( sc)
injections. Nevertheless, injection and hy persensitivity  reactions may  occur and the possibility  
of hitherto unforeseen side effects and allergic reactions to interventions, which can result in 
severe damage and even death, must alway s be considered.
2.2.4.2 Human Experience
So far osocimab has been tested in 4 P hase 1studies (Studies #17188, 17956, 17780, 19513)
with either iv or sc administration in healthy  volunteers (175 participants received osocimab 
up to 10 mg/kg iv) ,as well as in a study in patients unde rgoing total knee arthroplasty  for the 
prevention of VTE (#17664 FOXTROT stud y, 587 participants received osocimab up to 1.8 
mg/kg).
In the single dose Phase 1studies #17188 (study  report available) and #17780 and #17956 
(clinically  completed, reporting ongoing ), osocimab administrations were safe and well 
tolerated. No drug related serious adverse events (SAEs) were reported. Further details can be 
found in Section
5.2.3 of theInvestigator’s Brochure ( IB).
There were no clinicall y relevant bleeding event s, no relevant bleeding time prolongations 
and no signs or symptoms for hidden bleedings in the single dose 
Phase 1 studies.
In the multiple dose study  #19513 , which investigated two dose steps, two bleeding events of 
a moderate severit y were reported in the dose step 1 (
loading dose 100 mg sc; maintenance 
dose 35 mg sc) of the study : bleeding hemorrhoids and rupture of t ympanic membrane of the 
right ear. These hematomas were also assessed as not related to the study  intervention .In dose 
step 2 (loading d ose 210 mg sc
; maintenance dose 105 mg sc ), an intra -cranial hemorrhage 
was observed. The sponsor together with external experts performed a thorough evaluation of 
the case including follow -up Magnetic Resonance Imaging (MRI ). In conclusion, and 
although the contribution of osocimab cannot be excluded, the overall benefit risk assessment
for osocimab has not changed according to the data generated so far, specifically  as from the 
image interpretation there is a greater than 50
% likelihood for an underly ing arteriovenous 
(AV)- malformation/cavernoma as the underlying cause for the bleeding event . 
In summary , bleeding events in the single dose studies and in the multiple dose study  in 
healthy  volunteers did not indicate any  incre ased risk of bleeding. 
In a Phase 2astudy  ( # 17664, FOXTROT), osocimab was administered in patients undergoing 
elective TKA. This was a randomized, active comparator controlled, multicenter stud y to 
assess the safety  and efficacy  of different doses of osocimab for the prevention of VTE in 
comparison to enoxaparin and apixaban ( 22).  
In the FOXTROT study , 2 different administration schemes of osocimab were assessed: post -
surgery  administration (part A) and pre -surgery  administration (part B).  A total of 813
patients were randomized in the overall study
.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  20of 77
Part A investigated osocimab at single iv doses of 0.3, 0.6, 1.2, and 1.8 mg/kg. Part B 
investigated osocimab at single iv doses of 0.3 and 1.8 mg/kg.
Overall, FOXTROT showed that FXIa inhibition is effective for the prevention of VTE in 
patients undergoing TKA whether administered post -or pre -operativel y. Osocimab
demonstrated good hemorrhagic as well as non -hemorrhagic safet y and good tolerability ( 22). 
Further details can be found in the latest available version of the Invest igator's Brochure, 
which contains comprehensive information on the test drug.
Furthermore, a small Phase 1, observer-blind, multicenter, placebo- controlled study  is 
ongoing in patients with ESRD to assess the safety and tolerability  and to characterize the PK 
and the PD of different doses of osocimab (sc and iv) in this patient population (Study  
#20046). So far 13
patients with ESRD received a single iv dose of osocimab (0.3 mg/kg or 
1.2 mg/kg). No clinically significant bleeding events (i.e. major or clini cally  relevant non -
major bleeding) occurred after stud y drug administration nor were an y treatment -emergent 
SAEs reported, so far.
2.2.4.3 Rationale for the Development of Osocimab in ESRD Patients
The aim for the development of osocimab in patients with ESRD isto prevent 
thromboembolic events without increasing the riskfor bleeding events, as it is known from 
currentl y available anticoagulation therapies, which could provide a favorable benefit risk 
profile in patients with ESRD on hemodialy sis. Due to the characteristics of osocimab as a 
monoclonal antibody  targeting FXIa additional benefits suit very well tothe ESRD patient 
population:
Low dosing frequency  of once a month subcutaneous injection , which does not add to 
the alread y high pill -burden in this 
patient population.
Low risk for drug-drug interaction via Cytochrome P450 (CYP )enzy mes in the liver. 
Generally , monoclonal antibodies are metabolized to peptides and amino acids in 
several tissues, by circulating phagocy tic cells or by their target antig en-containing 
cells (23). In contrast to many  other drugs thatare taken by ESRD patients, osocimab 
will not interfere with other drugs that are metabolized in the CYP system of the liver 
as it is metabolized via other pathway s. 
No influence of plasma concentrations is expected with impaired kidney function as 
the drug is not excreted via this pathway . Furthermore, due to the large size of 
osocimab it not expected to be dialy zable.
2.3 Benefit/Risk Assessment
Due to the higher bleedin g risk of ESRD patients and the unproven benefits of currently 
available anticoagulation therap y in these patients, most hemodialysis patients are not treated
for the prevention of thromboembolic events. 
Targeting factor XI may  attenuate thrombosis without increasing the risk for bleeding. The 
separation of bleeding and efficacy  might be explained by  the fact that inhibition of FXIa 
affects the intrinsic and propagation pathway s, but keeps the extrinsic pathway  unaffected, 
which is activated in case of ves sel injury .
Based on the results of relevant animal models, known cases of human FXI deficiency , 
clinical experience with compounds with a similar mode of action (second -generation 
antisense oligonucleotide), initial clinical testing in healthy  volunteers, and most importantly  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  21of 77
patients undergoing TKA and receiving osocimab post- and pre -surgery , osocimab is a 
promising new drug candidate with the potential to prevent thromboembolic events with a 
low risk for bleeding. Potential risks such as bleeding, throm bocy topenia, hy persensitivity / 
injection -
related reactions will be closely  monitored during this trial . Strict inclusion and 
exclusion criteria are applied to exclude ESRD patients who are at high errisk for bleeding 
events. Due to the long half-life of th e compound in plasma , participants will be kept under 
observation for approximately  5 months after the last administration of osocimab. 
A DMC will frequentl y review safet y data toensure the safet y of the participants in the 
ongoing stud y
. Further details can be found in the DMC charter.
More detailed information about the known and expected benefits and risks and reasonabl y 
expected adverse events of osocimab may  be found in the I nvestigator’s Brochure.
2.3.1 Risk Assessment
Risk assessment for osocimab is described in Table 2–1.
Table 2
–1: Risk Assessmen t for Osocimab
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Hemorrhage (Bleeding) Risk factor associated with 
ESRD due to uremia -induced 
endothelial dysfunction
Increased bleeding risk due to 
routinely administered 
anticoagulant and antiplatelet 
agents to reduce risk of 
thromboembolic events and for 
dialysis maintenance
So far, no increased risk of 
bleeding across studies and 
doses for osocimab was 
identifiedSpecific in -and exclusion 
criteria to be applied
Reporting as primary safety 
outcome 
Regular hematological
laborator y assessment (see 
Section 1.3)
DMC will frequently review all 
safety events including bleeding 
events
CIAC will adjudicate all 
suspected bleeding events
Thrombocy topenia Osocimab reduce sdose and 
concentration -dependent lyFXI 
activity and prolong saPTT
(expected mode of action)Specific in -and exclusion 
criteria to be applied
Regular safety laboratory 
assessment (see Section 1.3)
Reporting as adverse event of 
special interest and stopping 
rule for drug administration (see 
Section 8.3.8 )
DMC will frequently review all 
safety events laborator y results
Hypersensitivity Observed cases of infusion or 
hypersensitivity reactions were 
rare and of mild degree in 
healthy volunteers
Inparticipants undergoing TKA, 
frequency of hypersensitivity 
and infusion -related reactions 
were low and comparable 
across treatment groups
including comparators 
(enoxaparin and apixaban)Reporting as adverse event of 
special interest ( see S ection 
8.3.8 )
DMC will frequently review all 
safety events
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  22of 77
Table 2–1: Risk Assessmen t for Osocimab
Potential Risk of 
Clinical SignificanceSummary of Data/Rationale for 
RiskMitigation Strategy
Development of anti -
drug a ntibodies (ADA) 
and neutralizing 
antibodies (NAB)In two Phase 1studies (#17188 
and #17780) t he majority of 
participants did not develop anti -
osocimab antibodies ;
participants with ADA- or NAB -
positive samples had low titers 
and did not show altered plasma 
concentrations of osocimab or 
unexpected PD or safety 
findings . In participants 
undergoing TKA, a small 
number of anti -osocimab 
antibodies (ADAs) and NAB s
were detectedMeasurements of ADA/NAB
formation over the course of 
the study (see Section 8.9)
Abbreviations: ADA =anti-drug antibodies , aPTT = activated partial thromboplastin time , CIAC =Central 
Independent Adjudication Committee , DMC =Data Monitoring Committee , ESRD =end-stage renal disease , 
NAB = neutralizing antibodies , PD= pharmacodynamic(s), TKA =total knee arthroplasty
Currently  available preclinical and clinical data regarding the important potential risks 
including the assessment of the safet y from the clinical studies do not indicate an unfavorable 
risk profile for osocimab.
2.3.2 Benefit Assessment
The potential benefit of receiving study  intervention during study  duration may alread ybe a 
reduce d risk for thromboembolic events in participants with ESRD , although this has no t yet 
been pr oven clinicall y.Furthermore, t his study  will contribute to develop new therapies in an 
area of high medical need, specificall y as patients with ESRD are often excluded from clinical 
trials due to their specific risk profile.
2.3.3 Overall Benefit: Risk Conclusion
Taking into account the potential benefits of this new compound , the potential risks identified 
in association with osocimab are justified b y the anticipated benefits that may  be afforded to 
participants with ESRD .Currently  available preclinical and clinical data do not indicate an 
unfavorable risk profile for osocimab.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  23of 77
3. Objectives and Endpoints
Objectives and endpoints are listed in Table 3–1. 
Table 3
–1: Objectives and Endpoints
Objectives Endpoints
Primary
To clinically assess the safety and 
tolerability of different doses of osocimab 
administered subcutaneously once a month 
during ma in treatment p eriod as compared 
to placeboComposite of major and clinically -relevant 
non-major bleeding events ( in alignment with 
ISTH guideline s)as assessed by blinded 
CIAC
Composite of moderate and severe AEs and 
SAEs
Secondary
To assess the change of key PD parameter 
from baselineaPTT, FXIa activity at trough levels after 6 
months
Tertiary/Exploratory
To clinically assess the efficacy of osocimab 
during ma in treatment p eriod
To evaluate the anticoagulant effect of 
osocimab on the extracorporeal blood circuit 
by the assessment of a semi -quantitative 
clotting score (SQCS) 
To evaluate the impact of osocimab on the 
AVaccess for pa rticipants with fistulas or 
grafts
To assess key  PK parameter
To explore additional PK/PD parameters, 
biom arkers and biomarker genetics
To further investigate the study intervention
(i.e. mode -of-action -related effects and / or
safety ) and to further investigate
pathomechanisms deemed relevant to
cardiovascular and renal diseases and
associated health problemsComposite endpoint consisting of: vascular 
death [due to MI, stroke, PE and SE], non -
fatal stroke, non -fatal MI, major amputation 
of vascular etiology, acut e limb ischemia and 
symptomatic VTE as assessed by blinded 
CIAC
Incidence of thrombosis of the arteriovenous 
fistulas or grafts 
SQCS
AVaccess bleeding score
Osocim ab trough levels
Various biomarkers and biomarker genetics 
may be explored (e.g. ,diagnostic, safety, 
population PK, PD,monitoring, or potentially 
predictive biomarkers )
Abbreviations: AE= adverse event, aPTT = activated partial thromboplastin time , AV=arteriovenous , 
CIAC = Central Independent Adjudication Committee , ISTH =International Society on Thrombosis and 
Hemostasis , MI= myocardial infarction , PD= pharmacodynamic(s) , PE = pulmonary embolism , 
PK= pharmacokinetic(s) ,SAEs =serious adverse events, SE= systemic embolism ,SQCS =semi -quantita tive 
clotting score , VTE = venous thromboembolism
The primary  objective is to assess the safet y under an osocimab concentration which is 
expected to be maintained during a chronic treatment. Thus the attributes constituting the 
primary  estimand are the following:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  24of 77
Population: The population consists of ESRD patients, further defined by  the in -and 
exclusion criteria, who received study  intervention at least once.
Variable:
a.Time from first dose of intervention to treatment emergent major and clinically -
relevant non- major bleedin g events (in alignment with I STH guidelines) up until 30 
days after last study  intervention
b.Time from first dose of intervention to moderate or severe AEs and SAEs up until 30 
days after last study  intervention
Treatment: Low/high-dose osocimab or matching placebo on top of standard of care
Intercurrent events: Of interest is the response to treatment while the participant is
alive (intercurrent event “death”) and 
exposed to study  intervention ( intercurrent event “premature discontinuation of 
treatment”),
i.e. both intercurrent events are handled using the same strategy  “while alive” or “while on 
treatment”.
Population -level summary: Hazard ratios comparing each of the osocimab dose groups with 
the placebo group as estimated from Cox proportional h azards models
.
Please refer to Section 9.4for further details.
4. Study Design
4.1 Overall Design
Study  20115 is a covariate -adaptive randomization, double -blind, parallel group , placebo -
controlled , multi -center study  to assess the safet y and tolerability  of monthly  administrations 
of a low and high dos e cohort of osocimab given subcutaneousl y in ESRD patients on 
hemodialy sis. In this protocol , the term hemodial ysisincludes hemodiafiltration . The overall 
study  design is depicted in 
Figure 1–1.
Approximately  600 participants (up to 750) from a pproximately  150 sites are planned to be 
randomized and will receive either osocimab (200 participants on each dose arm), or placebo 
(200 participants, i.e. 100 participants receiving low dose volume placebo and 100 
participants receiving high dose volume placebo).
The following regions are planned to be included: North America , Europe, Asia Pacific .
The planned stud y will consist of:
Screening 
period (visit 1): up to 14 day s
Randomization (visit 2) :1 day
Pre-treatment period (from visit 2until visit 4) :7 day s
Main treatment p
eriod (from visit 5 until EOMT visit ):6 months
Extension treatment period (from visit 19 until EOET visit ):up to 12 months
Follow -up period (from visit 32 until visit 35 ):4 months after end of treatment 
(EOMT or EOET )
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  25of 77
Informed consent form will be obtained at the beginning of the screening period. During the 
screening period ,participant ’s eligibility evaluations will be performed. Participants will be 
randomized either toosocimab or to placebo using a covariate- adaptive randomization 
technique (minimization methods) (for details see Section 6.3).
During the 
pre-treatment period , which will serve as a baseline period, a series of 3 
hemodialy sis sessions will be performed.
Unfractionated or low molecular weight heparin 
(UFH/LMWH) is allowed as anticoagulation for maintenance of hemodialysis treatment
during the whole study  duration .
The study  intervention will be administered subcutaneously abdominal with one single 
loading dose at visit 5 and monthly maintenance doses from visit 8 onwards until the end of 
the extension treatment period with an overall maximum of 18 months of treatment . The main 
treatment period consists of 6 months of treatment as this time frame is deemed to be the 
minimum clinically  relevant treatment time to assess osocimab as chronic life -time treatment 
in an appropriate manner and in preparation for Phase 3. 
Study  intervention will be administered during the extension treatment period for up to a 
maximum of 1 2months or until the last pa rticipant randomized to th estudy  has performed the 
EOMT visit (whichever comes first).
Thetreatment period (main or extension) 
will end with the study  assessments performed 30 
days after the last study  intervention administration.
The follow -
up period is an observational period of 4 months, i.e. ends approximately  5 
months after th e administration of the last dose of osocimab.
All suspected bleeding and cardiovascular (CV) or thromboembolic (TE) events occurring 
after signing informed consent ( randomiz ed participants only )
will be adjudicated by the
CIAC in a blinded fashion ;blinded to treatment allocation and dose cohort (details are 
described in the CIAC charter) .
The procedures followed by  theCIAC are detailed in the CIAC charter. Detailed instructions 
regarding documentation, reporting and transferal ofadjudication dossiers will be provided in 
a study  specific guidance document .
A DMC will frequentl y review safet y data toensure the safet y of the pa rticipant s in the 
ongoing stud y
. Further details can be found in the DMC charter.
Details of study  procedures and their timing are summarized in the SoA (see Section 1.3).
4.2 Scientific Rationale for Study Design
This is the first multiple dose study  of osocimab in ESRD patients with the aim to investigate 
the safet y, tolerability  and PK/PD after chro nic monthly  treatment with subcutaneous 
administrations in comparison to placebo. No established treatment exists for the prevention 
of thromboembolic events in patients with ESRD.
The selecti on criteria were chosen to exclude patients from the study , who may  potentiall ybe 
exposed to specific risks after administration o f osocimab
, as well as all patients with
conditions that may  have an impact on the objectives of the study .
A main treatment period of 6 months until the primary endpoint assessment is deemed to be 
appropriate to assess the safet y, tolerabilit y and efficacy of osocimab for anenvisaged chronic 
treatment regimen. However, participants will receive osocimab for a maximum of 18 months 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  26of 77
which will generate additional long -term safet y data and allow participants to potentially  
benefit from long -term treatment .
The study  procedures were planned to be as close as possible aligned with the usua l dialy sis 
procedure sin order to limit the extra burden for participant s.
The envisaged indication for osocimab is prevention of thromboembolic events in male and 
female patients with ESRD undergoing hemodial ysis.
4.3 Justification for Dose
The medium doses (0.6and 1.2 mg/kg iv single dose administration) tested in the FOXTROT 
study  were identified as the most promising doses to be tested in further studies , as they  
showed efficacy  numerically  comparable to that with enoxaparin and apixaban and were not 
associated with an y primary  safety  event, i.e. clinical significant bleeding event (22)(further 
details on FOXTROT can be found in the current version of the IB) .The doses tested in 
FOXTROT were 
substantially  lower than the doses that were administered during the first
Phase 1study  (upto 10 mg/kg iv).It is currently  assumed that the dose level s which were 
efficacious and safe in the FOXTROT trial will be safe and efficacious for the prevention of 
thromboembolic events in ESRD patients as well . The selected single iv doses from 
FOXTROT were translated into comparable sc doses independent from body  weight (i .e.
fixed dosing) 
taking into account the bioavailability  of sc administration . It was the aim to 
achieve with monthly  fixed sc doses similar troughlevel s (plasma concentration 
approximately  one month after dosing )as in FOXTROT at the primary  endpoint assessment 
(approx. 10-14 daysafter dosing ) . Therefore, osocimab doses needed to be adapted to achieve 
the FOXTROT exposure level after that longer period of one month . Furthermore, therapeutic
drug level should be reached as soon as possible after initiation of treatment to allow for an 
immediate treatment effect . Therefore, a loading dose concept was developed and tested in a
multiple dose Phase 1study  (#19513). This loading dose concept provides with a single 
(higher )
loading dose (compared to the maintenance doses) a rapid achievement of a 
therapeutic drug concentration and ensures stead y state exp osure alread y from study drug 
initiation .
As already tested in multiple dose study  #19513, i n this study  the sc dose administration will 
be independent from the body  weight (BW) (fixed dose concept) .This issupported b y 
preliminary  population PK anal ysesof Phase 1 data indicating that BW -adjusted dosing and 
flat dosing provide similar exposure distributions, with no clear advantage to both dosing 
approaches with respect to reducing variability  in pharmacokinetics.
When the fixed doses of the high dose cohort of 210 mg (LD) and 105 mg (MD) and are 
back -converted to BW -adjusted dosing, the corresponding sc doses for a pa rticipant of 80 kg 
will be 2.625 mg/kg and 1.3125 mg/kg BW, respectively . This is below 6 mg/kg BW sc, a
dose alread y shown to be safe in a Phase 1study  (#17780 ).
In analternative scenario of administering fixed doses to a light weight pa rticipant of 50 kg, 
thecalculated BW -
adjusted sc doses would be 4.2 mg/kg BW for a flat dose of 210mg and
2.1mg/kg BW for 105 mg. For both, the low and high dose cohort ,and both BWs the loading
and maintenance doses are below 6 mg/kg BW sc that were tested in the Phase 1 study  
(#17780) .Additionally , the sc doses of the high dose cohort of 105 mg (MD) and 210 mg 
(LD) have alread y been tested in multiple dose study  #19513 (administration on s tudy days 1, 
29, 57 and 85 ).Importantly , all doses intended for the current study  are considerabl y lower 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  27of 77
than the highest tested iv dose of 10 mg/kg BW, which was has been shown to be safe and 
well tolerated in healthy  volunteers ( #17188).
4.4 End of Study Definition
A participant is considered to have completed the study if he/she has completed at least the 
main treatment period of the study  including the last visit (EOMT) .
The primary  completion of the study  is defined as the date of the last visit of the 
last 
participant in the main treatment period. 
The end of the stud y is defined as the date of the last visit of the last participant in the study  
globall y.
5. Study Population
Prospective approval of protocol deviations to recruitment and enrollment criteria , also known 
as protocol waivers or exemptions, is not permitted.
The study  population will consist of stable end -stage -renal disease patients requiring 
hemodialy sis(including hemodiafiltration) sessions for approx. 3 times per week at least 9 
hours a wee k with no restriction to vascular access (e.g., catheter , AV fistulas and graft are 
allowed
).
5.1 Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
Age
1. Participants must be at least 18 y ears of age
Type of Participant and Disease Characteristics
2. Patients with end- stage renal disease on hemodialy sis(including 
hemodiafiltration )for ≥3 months, receiving dial ysis at least 9 hours a week and 
stable in the view of the investigator
Weight
3. Body weight of at least 50 kg
Sex
4. Male and/or female 
Contraceptive use b y men or women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.
For details see Section 10.4.
Informed Consent
5.
Capable of giving signed informed consent as describ ed in Section 10.1.3 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (I CF) and in this protocol
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  28of 77
5.2 Exclusion Criteria 
Participants are excluded from the study  if any of the following criteria apply :
Medical Conditions
1. Recent (<6 months before screening) clinicall y significant bleeding
2. Hemoglobin ( Hb)< 9.0 g/dL
3. Platelet count < 100 x 109/L 
4. aPTT or PT > ULN (upper limit of normal)
5. Hepatic disease associated with AL T> 3x UL N,or total bilirubin >2x UL N with 
direct bilirubin > 20% of the total
6. Sustained uncontrolled hypertension (diastolic blood pressure ≥100 mmHg and/or 
systolic blood pressure ≥ 180 mmHg) 
7. Known intracranial neoplasm, arteriovenous malformation or an eurysm
8. Known bleeding disorders e.g. , von-Willebrand disease or Hemophilia A, B or C
9. Recent (<3 months before screening) thromboembolic event, e.g. ,acute coronary  
syndrome, stroke or VTE (except dialy sis access thrombosis)
10. Recent (<3 months before screening) major surgery  or scheduled major surgery  
during stud y participation
11. Scheduled living donor renal transplant during study  participation 
12. Persistent heart failure as classified b y the New York Heart Association (NYHA) 
classification of 3 or higher
13. Receiving antiplatelet therapy  except dail y ASA (acetylsalicy licacid)
≤ 150 mg/day
14.
Receiving anticoagulation in therapeutic doses, other than standard 
anticoagulation during the hemodial ysis procedure
15. Life expectancy  less than 6 months
16. Active malignancy  requiring treatment during study  participation (except non -
melanoma skin cancer, or cervical carcinoma in situ)
17. Known hy persensitivity  to the investigational drug or to inactive constituents of 
the study  drug
Prior/Concurrent Clinical Study Experience
18. Participation in a nother clinical study  with an investigational medicinal product
within 30 day sor within 5 half -
lives of such, whichever is longer, prior to 
randomization andduring the stud y
Other Exclusions
19. Any other conditions, which, in the opinion of th e investigator or sponsor would 
make the subject unsuitable for inclusion
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  29of 77
5.3 Lifestyle Considerations
No restrictions during any of the stud y periods pertaining to lifest yle and/or diet apply .
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently randomized . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participants to meet the Consolidated Standards 
of Reporting Trials (CONSORT) publishing requirements and to respond to queries from 
regulatory  authorities. Minimal information includes demography , screen failure details, and 
eligibility  criteria.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescreened once. Rescreened participants should be assigned a new participant identification 
code ( PID
) and sign a new i nformed consent form.
Re-screening is allowed only  if an y of the following applies: 
The participant had successfully  passed the screening procedures, but could not start 
subsequent treatment on schedule. 
The in- / exclusion criteria preventing the participant’s initial attempt to participate 
have been changed (via protocol amendment). 
The participant suffered from a temporary  and not clinical relevant disease , e.g., a 
common cold.
In an y case, the investigator has to ensure that the repeated screening procedures do not 
expose the participant to an unjustifiable health risk. Also, for re-screening, the participant has 
to re-sign the informed consent form, even if it was not changed after the part icipant’s 
previous screening.
Suspected events of screen failures will not be submitted to the CI AC.
6. Study Intervention
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device (s) intended to be administered to a study  participant according to 
the study  protocol.
6.1 Study Interventions Administered
The following stud y interventions will be administered in the stud y:
Osocimab ( BAY 1213790) : sponsor ’s study  drug under investigation
Placebo to osocimab
Different doses will be achieved b y administering a different volume :
Low dose cohort
105mgsingle loading dose as subcutaneous abdominal injection at visit 5, followed 
by monthly  (i.e. 30 day s ± 3 day s) maintenance doses of 52.5 mg starting at visit 8
until the end of the extension treatment p eriod . Placebo will be administered 
subcutaneousl y in the same manner as osocimab.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  30of 77
High dose cohort:
210 mg single loading dose as subcutaneous abdominal injection at visit 5, followed 
by monthly  (i.e. 30 day s ± 3 da ys) maintenance doses of 105 mg starting at visit 8 
until the end of the extension treatment p eriod. Placebo will be administered 
subcutaneousl y in the same manner as osocimab.
Participants will be treated up to 18 months.
Osocimab/ placebo is administered within one hour ( 60 min utes) prior to start of dial ysis 
session by  site personnel at site .
Further details forstudy  intervention sare described in Table 6–1.
Table 6
–1: Study Interventions
Study 
InterventionOsocimab
low doseOsocimab
high dosePlacebo to osocimab 
Intervention 
Nameosocimab osocimab placebo to osocimab
Type drug drug placebo
Dose 
Formulationsolution solution solution
Unit Dose 
Strength(s)150 mg/mL 150 mg/mL NA
Dosage Level(s)105 mg (LD) once,
52.5 mg (MD) monthly210 mg (LD) once, 
105mg (MD) monthly NA
Route of 
Administrationscinjection scinjection scinjection
Use experimental experimental Placebo
Packaging and 
LabelingStudy intervention will 
be provided in 6 mL 
glass vials. Each vial 
will be labeled as 
required per countr y 
requirement .Study intervention will 
be provided in 6 mL 
glass vials . Each vial 
will be labeled as 
required per countr y 
requirement .Study intervention will 
be provided in 6 mL 
glass vials. Each vial 
will be labeled as 
required per countr y 
requirement .
Current/Former 
Name(s) or 
Alias(es )BAY 1213790 BAY 1213790 NA
Abbreviations : LD =loading dose, MD =maintenance/ monthly dose , NA =not applicable
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  31of 77
6.2 Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study  may  receive study  intervention a nd only  
authorized site staff may  supply  or administer study  intervention. All study  
intervention must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with 
access limited to the investigator and authorized site staff.
3. The investigator or the head of the institution (where applicable) is responsible for 
study  intervention accountability , reconciliation, and record maintenance (i.e., receipt, 
reconciliation, and f inal disposition records).
4.Further guidance and information for the final disposition of unused study  
interventions are provided in theInvestigator Site File . 
Osocimab is 
supplied in 6 mL  clear, single -use injection glass vials as a solution. Osocimab is 
a solution with a concentration of 150 mg/mL at pH 5.0. The total content of the glass vial is 
2.3 mL , corresponding to 345 mg of osocimab . From the total 2.3 mL , 2.0 mL (i.e. 300 mg) 
aretheextractable volume and 0.3 mL (i.e. 45 mg) are overfill. Placebo to 
osocimab is 
supplied in 6 mL clear, single -use glass vials as a solution. Further details can be found in the 
handling instruction provided separatel y.
6.3 Measures to Minimize Bias: Randomization and Blinding
After a participant has signed an infor med consent form,  the unique participant identification 
number ( PID) will be assigned via Interactive Web Response Sy stem (IWRS). If a participant 
is re- screened, a new PID will be assigned. The PI D is a 9 -digit number consisting of: 
Digits 1 to 5 = Unique site number 
Digits 6 to 9 = Unique participant number (current participant number within the study  site)
The unique participant number will start with 5for each participant.
All participants will be centrally  assigned to randomized study  intervention using anIWRS. 
Study  intervention will be administered at the study  visits summarized in SoA (Section 1.3). 
Before the stud y is initiated ,thelog in information anddirections for IWRS will be provided 
to each site.
Covariate -adaptive randomization techniques (minimization methods) will be utiliz ed taking 
into account the following baseline covariates (weights of the baseline covariates for the 
calculation of imbalance in brackets):
Region (categorical) ( 17.0%)
Age ( 17.0%)
Prior major adverse cardiovascular event (MACE ) (17.0%)
Dialy sis access via catheter (17.0%)
L
ow-dose ASA use (Yes/No) ( 17.0%)
Diabetes (Yes/No) ( 7.5%)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  32of 77
Atrial fibrillation (Yes/No) (7.5 %)
Sponsor, participants and investigators are being blinded with respect to active treatment 
versus placebo, but not blinded to dose cohort (low or high dose) .The CIAC will be blinded 
to the participant’s treatment allocation and dose cohort .The DMC will review blinded data 
and will have access to unblinded data as outlined in the DMC charter.
In order to maintain the blind, osocimab and matching placebo will be packaged in identical 
vials and each vial will be labeled with a unique, pre -printed number.
The IWRS will be programmed with blind- breaking instructions. In case of an emergency , the 
investigator has the responsibility for determining if unblinding of a participant’s intervention 
assignment is warranted. If the investigator is unavailable, and a treating physician not 
associated with the stud y requests emergency unblinding, the emergency unblinding requests 
are forwarded to the emergency  medical advice 24 hours/7 day  service. Participant safet y 
must alway s be the first consideration in making such a determination. If the investigator 
decides that unblinding is warranted, the investigator should make every  effort to contact the 
sponsor prior to unblinding a participant’s intervention assignment unless this could delay  
emergency  treatment of the participant. If a participant’s intervention assignment is 
unblinded, the sponsor must be notified within 24 hours after breaking the blind. The date and 
reason that the blind was broken must be recorded in the source documentation and case 
report form, as applicable.
Bioanal ytics and pharmacometrics staff will be unblinded according to Bayer SOPs. 
Bioanal ysis and population PK ( popPK ) evaluation might be started prior to database lock: if 
this is applicable, appropriate measures will be taken to maintain blinding of the study  team, 
e.g., data will be stored separately , and members of the study  team will not have access to 
unblinded data.
6.4 Study Intervention Compliance
When participants are dosed at the site, they  will receive study  intervention directly  from the 
investigator or designee. The date and time of each dose administered in the clinic will be 
recorded in the source documents an d recorded in the electronic case report form ( eCRF ). The 
vial number(s) and study  participant identification will be confirmed at the time of dosing. To 
monitor compliance, drug accountabilit y information will be documented for each participant.
6.5 Concomitant Therapy
Any medication or vaccine (including over -the-counter or prescription medicines, vitamins, 
and/or herbal supplements) that the participant is receiving between signing of the I CF and 
the end of the study must be recorded along with:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
Specificall y, medications influencing coagulation or platelet aggregation even if taken before 
the informed consent was signed should also be recorded in the eCRF (up to 6 months prior to 
randomization) .
Prior and concomitant medications that should be stopped at least 10 day s prior to start of 
study  intervention , i.e. 3 day s prior to randomization and not allowed during the stud y are:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  33of 77
1. Antiplatelets (e.g.,clopidogrel, ticagrelor, dipy ridamole, acet ylsalicy lic acid 
>150mg/day ) 
2.Vitamin K antagonists (e.g. ,phenprocoumon, warfarin- sodium) 
3.Unfractionated heparins and LMWH other than for dialy sis maintenance
4. D irect oral anticoagulants (e.g. , rivaroxaban, apixaban, dabigatran, edoxaban).
Participants who cannot stop the respective treatment have to be excluded from the 
study .
5.Thromboly tic drugs for sy stemic use (e.g., streptokinase, alteplase, tenecteplase, etc.)
For participants, who are rec eiving ASA ≤ 150 mg/day ,any dose adaptation should be 
avoided if possible
.Especially , during the main treatment period an y adaptation of the current
ASA dose or an y initiation of ASA should be avoided and should only  be done if medicall y 
necessary .
Surge ry, which is deemed necessary  should be performed under general anesthesia only . 
Spinal or epidural anesthesia is not allowed during the stud y. 
The Medical Monitor should be contacted if there are an y questions regarding concomitant or 
prior therap y.
6.6 Dose Modification
This protocol does not allow an ypre-planned alteration from the currentl y outlined dosing 
schedule (Section 6.1).
6.7 Intervention after the End of the St udy
No further intervention is planned after the end of the study . No long -term effects are 
expected that would need any  additional care or intervention.  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  34of 77
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal
7.1 Discontinuation of Study Intervention 
In rare instances, it may  be necessary  for a participant to permanentl y discontinue (definitive 
discontinuation) study  intervention. If stud y intervention is definitively discontinued, the 
participant will remain in the study  to be evaluated until the end of the follow -up period
. See 
the SoA for data to be collected at the time of discontinuation of study  intervention and 
follow -up and for an y further evaluations that need to be completed.
A participant must permane ntly discontinue study  intervention for an y of the following : 
The participant becomes pregnant. The pregnancy  will be reported per reporting 
procedures in Section 8.3.5 .
The pa rticipant is unwilling to continue study  intervention.
The participant experiences an AE (including clinically  significant bleeding 
[Sections 8.2.2 and 8.3]) or requires surgery  (Section 8.2.2.2) that in the judgment of 
the 
investigator necessitates permanent discontinuation of study  intervention.
The participant develops laboratory  test abnormalities that meet the stoppin g rule 
outlined in Section 8.3.8.1.
The participant moves their dialy sis care to a different hemodial ysis facility where the 
study  team cannot regularly follow the participant . All efforts should be made to 
conduct the post -treatment follow -up visits in person to complete all study procedures. 
If in-person visits by the pa rticipant are impossible, limited remote contact visits (e.g.,
phone) may  be conducted recording as much information as possible for eCRF entry .
At the discret ion of the i nvestigator due to participant non-compliance, or major 
protocol deviation(s) 
The sponsor has the right to withdraw a participant from the study  due to non
-
compliance, major protocol deviations or for safety reasons
A participant may permanently  discontinue study  intervention for an y of the following at the 
discretion of the investigator : 
The participant begins treatment with a disallowed concomitant medication as 
described in Section 6.5. 
The participant is no longer on regular maintenance hemodial ysis of at least 3 -times 
per week for a minimum of 9 hours per week, including a change in dial ysis modality .
If a participant permanently  discontinues study  intervention and is unwilling or unable to 
attend regular study  visits at the study  site, all possible efforts should be made to obtain 
information on the health status of the participant.
A participant may  be withdrawn from 
study  intervention at the discretion of the investigator 
for safety, behavioral , compliance, or administrative reasons. 
The reason for discontinuation of study  intervention must be recorded in the eCRF and source 
documentation. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  35of 77
7.1.1 Temporary Discontinuation 
This protocol does not allow an y pre-planned alteration from the currentl y outlined dosing 
schedule . However, there may  be rare circumstances due to which t he investigator may  need 
to temporarily  discontinue study  intervention for an adverse event (Sectio n8.3), bleeding 
event (Section 8.2.2) , or surgery  (Section 8.2.2.2) andany other reason not listed as reasons 
for discontinuation of study  intervention (Section 7.1) or withdrawal from the study  
(Section 7.2). 
The following guidance should be observed in case maint enance dosing cannot be 
administered according to dosing schedule.
Delay ed maintenance dosing:
Adose is delay ed if it is given up to 4-7 day sfrom the original schedule. The dose should be 
administered at the next possible time point , but not later than 7 days than originall y 
scheduled
.
Missed maintenance dosing:
Any dose which is delayed for more than 7 day s will be considered as missed dose. The dose
should be administered at the next possible time point , but not later than 60 (+3) days after the 
last given dose. There should be also minimum 30 days ± 3 day s between the doses. If the 
dose is delay edmore than 60 (+3) day safter the last given dose ,the participant will need to
move into the follow -up period. Onl y one maintenance dose can be missed (i.e. given > 7 
days after the originall y schedule ddosing and not later than 60 ( +3)days after the last 
actuall y administered dose) per main treatment or per extension treatment period. Between 
missed doses at least 5 regular maintenance doses should have been administered according to 
protocol , otherwise the participant will also need to move into the follow -up period. Obtain 
blood samples for PK/PD anal ysis 30 (±3) days after the date of the delay ed dose, if not 
already scheduled according to the study  protocol. 
7.2 Participant Discontinuation/Withdrawal from the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral, 
compliance, or administrative reasons. This is expected to be uncommon. 
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit 
should be conducted, as shown in the SoA. See SoA (Section 1.3) for dat a to be 
collected at the time of study  discontinuation and follow -up and for an y further 
evaluations that need to be completed.
The participant will be permanentl
y discontinued both from the study intervention and 
from the study  at that time.
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected before such a withdrawal of consent.
If a participant permanently  discontinues/withdraws from the study  and is unwilling or unable 
to attend regular stud y visits at the study  site, all possible efforts should be made to obtain 
information on the health status of the participant.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  36of 77
7.3 Lost to Follow Up
A participant will be considered lost to follow- up if he or she repeatedl y fails to retur n for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as soon 
as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should 
continue in the study .
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact attempts should be documented in the 
participant’s medical record.
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.
Data that have been collected until the time the participant is consid ered to be lost to follow
up may  be retained and continued to be used.
8. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue 
study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study  conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or recor d 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management ( e.g.,
platelet count) and obtained before signing of the ICF may  be utilized for screening or 
baseline purposes provided the pro cedures met the protocol
-specified criteria and were 
performed within the time frame defined in the SoA.
If deemed necessary  for an individual participant, the investigator or designee, at 
his/her discretion, may  arrange visits in addit ion to the scheduled stud y visits. 
Relevant unscheduled visits will be documented in the eCRF.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  37of 77
8.1 Efficacy Assessments 
The efficacy  will be assessed by anal yzing exploratively  the incidence of the following 
components
Death due to MI, stroke, pulmonary  embolism ( PE)and systemic embolism ( SE)
Non- fatal stroke
N
on-fatal MI
Major amputation of vascular etiolog y
A
cute limb ischemia
Symptomatic VT E 
Thrombosis of AV fistulas or grafts
Furthermore, the effect of osocimab on the clotting in the dial ysis circuit will be assessed by  
the SQCS. At the end of the hemodialysis procedure, the filter and line (including drip 
chamber/ air trap) will be examined by  the hemodialy sis nurse (or respective appropriate 
personnel) after rinsing the circuit. If possible the same r insing volume should be used within 
one participant throughout the course of the stud y.Clotting scores will be assigned as follows:
“0” clean filter and no visible clots in the drip chamber/air trap
“1”traces of coagulation in the filter and/or in the drip chamber/air trap
“2” intermediate state between “1”and “3”
“3” fully  clotted extracorporeal system resulting in an interruption of the 
hemodialy sissession
Adequate anticoagulation is defined b y a SQCS of less or equal “1”.
Additional det ails for assessment of SQCS can be found in a study  specific guidance 
document 
.
8.2 Safety Assessments 
During all contacts with the participant from signing the informed consen tform , investigators 
will check for and record the following in the eCRF :
Bleeding events
Adverse events, including a
dverse e vents of s pecial interest
Concomitant medication changes
Changes in dial ysis prescription
Planned time points for all safety  assessments are provided in the SoA in Section 1.3.. 
Abnormal safety  findings which have started after signing of 
informed cons entshould be 
reported as an AE/SAE. Clinically  significant abnormal findings will be reported as AEs in 
the eCRF.
AEs requiring submission to the CI AC are listed in Sectio n 8.3.9.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  38of 77
8.2.1 Main Safety Assessment
Incidence, severity  and seriousness of AE, and SA E, including bleeding events, as well as the 
causal relationship between an AE/SAE and the administration of the study  intervention will 
be assessed throughout the study .
In order to evaluate the safet y and tolerability of osocimab, AEs will be assessed as the main 
safet y endpoint .See Section 8.3for further information.
8.2.2 Bleeding Events
Major bleeding ( MB)andclinically -relevant non- major bleeding (CRNMB )events , as 
assessed b y CIAC, will be the primary safet y endpoint in this study . 
Randomized p articipants will be evaluated for occurrence of bleeding events continuously  
after signing informed consent up to the end of the post -treatment follow -up for all cohorts. 
All bleeding events (other than the normal bleeding from AVgraft or fistula post- dialy sis) 
will be reported as AE or SAE per Section 8.3andsubmitted to the CIAC.
However, bleeding after dialy sis from AV graft or fistulas is expected and will only  be 
reported as an AE /SAE and submitted to CI AC if there is a change in the pattern , duration or 
intensity  of bleeding in a participant , or if exceptional measures are taken for hemostasis 
beyond normal, relative to post -dialy sis bleeding that was observed in that 
participant over
(approximately )the prior 4 weeks.  
Bleeding afte r dial ysis from the AVfistula have also to be assessed b y the AV bleeding score 
(Section 8.2.2.1).
The CIAC will classify  bleeding events primaril y in alignment with the ISTH definitions (24):
Definitions in alignment with ISTH (Please refer to the adjudication charter for details):
Major bleeding (MB) is defined as symptomatic bleeding with one of the following:
Bleeding that contributed to death
Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with 
compa rtment s yndrome
Bleeding causing a fall in hemoglobin level of 2 g/dL (1.24 mmol/L) or more, or 
leading to transfusion of two or more units of whole blood or red cells
Clinically  relevant non -major (CRNM) bleeding is any  sign or s ymptom of hemorrhage (e.g.,
more bleeding than would be expected for a clinical circumstance, including bleeding found 
by imaging alone) that does not fit the criteria for the I STH definition of major bleeding but 
does meet at least one of the following criteria:
Requiring medical i ntervention by  a healthcare professional
Leading to hospitalization or increased level of care
Prompting a face to face evaluation (i.e. not a telephone or electronic communication)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  39of 77
8.2.2.1 Assessment of AV Access Bleeding
Severity  of bleeding at the dialy sis access will be assessed approx. 15 minutes after removal 
of the dialy sis needle(s) from the AV access according to the following categories 
(exploratory bleeding score):
“0” no access bleeding
“1” slow oozing
“2” overt bleeding
In case the AV access exhibits overt bleeding 15 minutes after removal of the dialy sis
needle(s) ( AVaccess bleeding score of 2), the investigator may  consider the reduction of
heparin (i.e. UFH, LMWH) for the subsequent dialy sis sessions during the treatment and
follow-up period. For such decision, the investigator should take all available participant
information into account (e.g., laboratory  values, concomitant medication, details of
hemodialy sis session, adverse events etc.).
In case catheter is used, the AV access bleeding is not applicable.
8.2.2.2 Recommendations for Bleeding and Surgery Management 
Bleeding
In general, the management of bleeding is at the discretion of the treating phy sician and local 
prescribing information should be consulted for usage in ESRD for any drug administered . 
Evidenced- based treatment recommendations for uremic bleeding in patient swith ESRD are 
summarized in Hedges et al, 2007 ( 25).
In case a pa rticipant experience s
a severe bleeding event (e.g.,bleeding that lead sto surgical 
procedures or transfusion of blood components or to prolonged hospitalization or bleeding  
into a critical organ or in close space )and further treatment of the participant is harmful in the 
view of the investigator, treatment should be discontinued and participants should be treated 
as medicall y indicated. So far no data for management of bleeding and surgery  under 
osoci mab have been gathered.
The following measures may be considered b y the investigators to control bleeding and are at 
thediscretion of the treating phy sician:
Mechanical compression or surgical intervention
Delay  of the next injection or discontinuation of treatment
Review and discontinue concomitant medications that could exacerbate bleeding
General volume management : fluid replacement & hemod ynamic support.
Transfusion (e.g., whole blood/packed cells/ fresh frozen plasma [ FFP]/platelets) with 
careful volum e management
Antifibrinoly tics (e.g., aminocaproic acid or tranexamic acid, consult local prescribing 
information for guidance on usage in patients with severe renal impairment/ESRD)
Desmopressin
Conjugated estrogens
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  40of 77
If bleeding cannot be controlled by  these measures, administration of the following may  be 
considered, if used as part of local practice (consult local prescribing information for guidance 
on usage in patients with severe renal impairment/ESRD) and are under discretion of the 
treating ph ysician :
Recombinant Factor VIIa (NovoSeven)
FEIBA
4-factor concentrate (prothrombin complex concentrate)
In vitro data with osocimib showed that the prolongation of aPTT and ROTEM CT induced 
by osocimab can be fully reversed by  recombinant FVIIa (NovoSeven) or factor eight 
inhibitor by pass activit y (FEIBA) . In in vitro experiments PCC (prothrombin complex 
concentrate) was not able to normalize aPTT and ROTEM CT. However, this may  be due to 
the inability  to show effects on the coagulation tests by  these measures (f urther details may  be 
found in the current version of the IB ).
As coagulation parameters are potentiall y unblinding these should onl y be reviewed if 
medically  indicated. 
Surgery
Major surgery (e.g. , surgical procedure involving an organ within the crani um, chest, 
abdomen, or pelvic cavity )or major procedures in tissue with high fibrinoly tic activity  (e.g. ,
gynecologic, urologic, or surgeries of the nasal and oral cavities) or surgeries with high risk 
for perioperative bleeding , should not be performed d uring the trial. However, if deemed 
medically  necessary  and surgery  cannot be postponed until the end of the follow -up period , 
the surgery  is onl y allowed to be performed under general anesthesia. Spinal or epidural 
anesthesia/analgesia is not allowed duri ng the study .Investigator sare encouraged to postpone 
surgeries whenever possible until the end of the study  including the 4 months follow -up 
period or at least as long as possible after the last study  intervention. Hence, study  
intervention should be imm ediately  discontinued if a participant is scheduled for the above 
mentioned surger ies. Participants who permanently  discontinue study  intervention due to a 
surgery  will enter the post -treatment f ollow -up period (Section 7.1).
Minor surgeries or surgeries with low bleeding potential (e.g. ,knee replacement surgery ) may  
be performed during the trial if deemed necessary  and can’t be postponed. Of note, during the 
FOXTROT trial participants have been operated for total knee replacement under full anti -
coagulation with osocimab (doses up to 1.8 mg/kg). Stud y interventions may be further 
administered after such surgery  if deemed appropriate by  the investigator and after careful 
post-operative 
assessment. Before restarting study  intervention administration of prohibited 
concomitant medication need s to be taken into account (Section 6.5).
If knowledge of treatment assignment will influence the choice of intervention to manage 
bleeding risk prior to or during the surgery  the investigator may  immediately  obtain the 
participant’s treatment assignment b y contacting IWRS.  I n this setting, it is appropriate to 
monitor coagulation parameters.  
Management of bleeding and surgery  of study participants may further be guided by  
published data regarding patients with inherited FXI deficiency. There have been reports in 
the literature about the successful use of tranexamic acid or ε-amino caproic acid in the 
management of non- ESRD, hemophilia C patients when undergoing surgery  (26). The local 
package insert need to be consulted for usage in patients with ESRD on dialy sis. In patients 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  41of 77
undergoing tooth extractions, i.e. an invasive procedure in tissue with high fibrinoly tic 
activity  in the orophary nx, Berliner et al. reported uneventful extractions in 19 patients with 
severe FXI deficiency  treated with tranexamic acid alone (1 g q.i.d.) started 12 h prior to 
surgery  and continued for 7 day s after surgery  (27). The administration of recombinant FVIIa 
in addition to tranexamic acid was also reported as a therapeutic option in patients with severe 
FXI deficiency  undergoing 
surgery  (28-29). O’Connell et al. reported effective hemostasis 
when a dose of 90 
μg/kg of recombinant FVIIa given eve ry two hours in the first 24 hours 
and every  4 hours in the second 24 hours, followed by  postoperative tranexamic acid for 7 
days, was used in patients undergoing major surgery . Subsequently , Livnat et al. showed that 
even a single dose of recombinant FVII a at a dose of 15-30 μ g/kg, along with 1 g of 
tranexamic acid given before surgery  and then every 6 hours post -surgery  for 7 -14 day s 
achieved satisfactory hemostasis in patients with FXI inhibitors undergoing major surgery  
(30). 
Please consider that for severe renal impairment/ESRD specific limitation or even 
contraindications for use of certain agents may  apply . This may  differ between countries.
8.2.3 Physical Examinations
A complete ph ysical examination will include, at a minimum, assessments of the 
cardiovascular, respiratory , 
gastrointestinal and neurological sy stems and will follow standard 
practice of the site . Height will only  be measured at screening visit . Weight will be measured 
pre-and post-hemodial ysis(dry-weight) .
8.2.4 Vital Signs
Vital signs will consist of 1 pulse and 1 blood pressure measurements. Vital signs will 
be measured after 5 minutes rest. 
Blood pressure and pulse measurements will be assessed pre-dialysis (with the 
exception of the screening visit), either in a supine or sitting position (preferably  in the 
same position for all visits), on the same arm at each visit, and using the appropriate 
size cuff. These measurements will be performed at the time points specified in the 
SoA (see Section 1.3). 
NOTE: The AV graft or fistula arm cannot be used to measure blood pressure.
8.2.5 Electrocardiograms
Single s tandard electrocardiograms (12 lead ECG) accordi ng to Goldberger / 
Einthoven and Wilson will be recorded pre-dialysis after resting for at least 5 min at 
the time points specified in the SoA (see Section 1.3).
All ECG print -outs will be identified with the PID as well as date and time of 
recording and will be attached to the participant’s 
file.
ECG printouts will be examined locall y by the investigator on the day of recording for 
safet y and quality. Any clinically  relevant abnormality  will be documented as an AE.
All suspected acute coronary  syndrome events need to be submitted to the CI AC for 
evaluation .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  42of 77
8.2.6 Clinical Safety Laboratory Assessments
See Section 10.2 for the list of clinical laboratory  tests to be performed and the SoA
(
Section 1.3)for timing and frequency . 
The investigator must review the laboratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
eCRF. The laboratory  reports must be fi led with the source documents. Clinically  
significant abnormal laboratory  findings are those which are not associated with the 
underly ing disease, unless judged by  the investigator to be more severe than expected 
for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or until the end of study should be repeated until the values 
return to normal or baseline or are no longer considered clinically significant by the 
investigator or the medical monitor .
If such values do not return to normal/baseline within a period of time judged 
reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
All protocol -required laboratory  assessment s, as defined in 
Section 10.2, must be 
conducted in accordance with the laboratory  manual and the SoA. 
If laboratory  values from non
-protocol spec ified laboratory  assessments 
performed at the institution’s local laboratory  require a change in participant 
management or are considered clinically  significant by  the investigator ( e.g.,
SAE or AE or dose modification), then the results must be recorded i n the 
eCRF.
Appropriate blood draws from the dialysis access for any type of blood sampling, 
collected from the hemodialy sis line(not directly  from the fistula, nor from any  vein 
on the fistula arm), or tunneled catheters are permitted. Whenever possible, the blood 
should be drawn under the same conditions (details are depicted in the laboratory  
manual) . 
Where possible for safety  laboratory , pediatric -sized blood volumes (as opposed to 
adult -sized blood volumes) are to be taken and blood collections should be combined 
to minimize the number of needle punctures.
During the screening visit, only  local laboratory  samples will be assessed to check the 
eligibility  of the patient. For details see Section 10.2.
Central lab results for PD parameters including coagulation parameters will not be provided to 
the sites, as these are potentially  unblinding. Investigators should also avoid local testing of
coagulation parameters, as these may  be unblinding, unless clinically  indicated.
8.2.7 Dialysis Information
8.2.7.1 Renal Replacement Therapy (RRT) Baseline Information (General 
Dialysis Information)
Current dialy sis prescription will be collected on the appropriate eCRF.
Note: anticoagulation use during hemodialy sis must be reported in the Concomitant 
Medication page in the eCRF.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  43of 77
8.2.7.2 Dialysis Prescription Changes
Changes to the dialy sis prescription and compliance with dial ysis will be recorded on the 
appropriate eCRF at v isits specified in the SoA.
Note: changes in anticoagulation use during hemodialysis must be reported on the appropriate 
eCRF page.
8.3 Adverse Events and Serious Adverse Events
AEs will be reported b y the participant (or, when appropriate, b y a caregiver, sur rogate, or the 
participant's legall y authorized representative).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE orSAE and remain responsible for 
following up AEs that are serious, considered related to the study  intervention or study  
procedures, or that caused the participant to discontinue the study  intervention orstudy  (see 
Section 7).
8.3.1 Time Period and Frequency for Collecting AE and SAE Information
All AEs/ SAEs will be collected from signing of 
informed consent until the last follow -up visit 
at the time points specified in the SoA (Section 1.3).
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Section 10.3. The investigator will 
submit any  updated SAE data to the sponsor within 24 hours of it being available.
Investigators are not obligated to activel y seek AE orSAE after conclusion of the study  
participation. However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y rela ted to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor. 
8.3.2 Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE and SAE and the 
procedures for completing and tran smitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3
Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and AE SIs (as defined in Section 8.3.8),
will be followed until resolution, stabilization, the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). Further i nformation on follow -up 
procedures is provided in Section 10.3.
8.3.4 Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator 
to the sponsor of a nSAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinical investigation are met. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  44of 77
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specific regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
For all studies except those utilizing medical devices investigator safet y reports must 
be prepared for suspected unexpected serious adverse reactions (SUSAR) according to 
local regulatory  requirements and sponsor policy  and forwarded to investigators as
necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information ( e.g., summary  or listing of SAEs) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify  the 
IRB/IEC, if appropriate according to local requirements.
Reporting of Disease -Related Events
Overall, in compliance with applicable
regulations, in the event of a SUSAR related to the 
blinded treatment, the participant’s treatment code will usually  be unblinded before reporting 
to the health authorities. Notifications of IEC/I RB and investigators will be done according to 
all applicab le regulations (see Section 8.3.4) with the restrictions described below.
During the study  there will be instances where AEs are also potential eff icacy  or safety  
endpoints.
The following efficacy  and pre -defined disease -related outcome events are expected in 
patients with ESRD
i. Bleeding
ii. Death due to MI, stroke, PE and SE
iii. Non-fatal stroke
iv. Non-fatal MI
v. Major amputation of vascular etiology
vi. Acute limb i schemia
vii. Symptomatic VTE 
viii. Thrombosis of AV fistulas 
or grafts
These will be recorded on the corresponding CRF page in the participant’s eCRF.
If any of the above listed outcome events fulfil the definition of SAEs as given in 
Section 10.3, the investigator must report them immediately  (within 24 hours of the 
investigator’s awareness) to the sponsor’s pharmacovigilance department as described in 
Sectio n10.3. However, SUSARs that derive from these efficacy  outcome events (as specif ied
above ii – viii: Death due to MI , stroke, PE and SE, non- fatal stroke, non -fatal MI , major 
amputation of vascular etiology , acute limb ischemia, sy
mptomatic VTE, thrombosis of AV 
fistulas or grafts ), including events indicative of those outcome events (details will be 
described in the adjudication charter and additional study  specific guidance documents) will 
be waived from unblinding and are not subject to expedited reporting to health authorities. I n 
case of unblinding, SUSARs may  be submitted blinded, either expedited or aggregated, to 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  45of 77
investigators and IEC/I RB. Unblinded SUSAR reports are submitted only  when required by  
local legislation.
8.3.5 Pregnancy
Details of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after signing of informed consent and until the last
follow- up visit (visit 35). 
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours 
of learning of the pregnancy  and should follow the procedures outlined in 
Section 10.4.
Abnormal pregnancy  outcomes ( e
.g.,spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy ) are considered SAEs.
As se rumbeta human chorionic gonadotropin (
βhCG)levels are high in pregnant and 
may be elevated in non- pregnant women with ESRD undergoing hemodialy sis, one 
measurement of high βh CG may  not be sufficient to establish pregnancy . Only  
sequential increasing levels of β hCG may  be considered for further investigation on 
pregnancy . If deemed necessary , a follow -up ultrasound may  be performed to confirm 
pregnancy . If a female participant becomes pregnant, she must permanently 
discontinue study  intervention.
8.3.6 Cardiovascular and Death Events
Not applicable.
8.3.7 Disease-Related Events and/or Disease -Related Outcomes Not 
Qualifying as AEs or SAEs
Bleeding after dial ysis from AV graft or fistulas is expected and will only  be reported as an 
AE or SAE if there is a chang e in the pattern or intensity  of bleeding in a participant, or if 
exceptional measures are taken for hemostasis beyond normal, relative to post -dialy sis 
bleeding that was observed in that participant over the prior 4 weeks.
8.3.8 Adverse Events of Special Intere st 
Adverse events of special interest have to be reported to the sponsor along the timelines set 
for SAEs, i.e. within 24 hours of the investigator’s awareness, as described in Section 8.3.1.
Declaration of an event as serious should only  occur if one or more of the serious criteria is 
applicable. Non -serious adverse events of special interest should not automatically  be 
upgraded to serious by  the reporting investigator.
Adverse events of special interest are:
Decrease in platelets below 75x 109/L or > 50 %decrease in platelet count from 
baseline 
Hypersensitivity  (i.e. any allergic reactions of ≥ CTCAE criteria 2 [Common 
Terminology  Criteria for Adverse Ev ents] or anaphy laxis)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  46of 77
8.3.8.1 Stopping Rule for Study Drug Administration in Case of 
Thrombocytopenia
In the event of a platelet count that is < 75,000mm3, or > 50% decrease in platelet count from 
baseline the initial measurement should be confirmed by  drawing re peat measurement (s)
within 2 weeks. The repeat measurement(s) must occur before further study intervention (i.e. 
study  drug administration). In the event that the platelet count has not recovered to 
> 100,000 mm3within 2 weeks , dosing of the participant will be postponed until the platelet 
has increased at least above 100,000 mm3.In the event that after resumed dosing 
thrombocy topenia ( <75,000 mm3) occurs again, study  drug
administration will be stopped 
permanentl y.A participant may  be withdrawn from study  intervention at any  time at the 
discretion of the investigator for safet y reasons (Section 7.1). 
8.3.8.2 Hypersensitivity R
eactions
Hypersensitivity  reactions will b e assessed according the Common Terminology  Criteria for 
Adverse E
vents of the National Cancer Institute (CTCAE v5.0), see Table 8–1. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  47of 77
Table 8–1: Common Terminology for Adverse Events Related to Immune System 
Disorders (CTCA E v-5.0)
Immune system disorders
Adverse 
EventGrade
1 2 3 4 5
Allergic 
reactionSystemic 
intervention not 
indicatedOral intervention 
indicatedBronchospasm; 
hospitalization 
indicated for clinical 
sequelae; 
intravenous 
intervention 
indicatedLife-threatening 
consequences; 
urgent 
intervention 
indicatedDeath
Definition: A disorder characterized by an adverse local or general response from exposure to an allergen.
Anaph ylaxis- - Symptomatic 
bronchospasm, with 
or without urticaria; 
parenteral 
intervention 
indicated; allergy -
related edema/ 
angioedema; 
hypotensionLife-threatening 
consequences; 
urgent 
intervention 
indicatedDeath
Definition: A disorder characterized by an acute inflammatory reaction resulting from the release of histamine 
and histamine -like substances from mast cells, causing a hypersensitivity immune response. Clinically, it 
presents with breathing difficulty, dizziness, hypotension, cyanosis and loss of consciousness and may lead to 
death.
Autoimmune 
disorderAsymptomatic; 
serologic or other 
evidence of 
autoimmune 
reaction, with 
normal organ 
function; 
intervention not 
indicatedEvidence of 
autoimmune 
reaction 
involving a non -
essential organ 
or function (e.g., 
hypothyroidism)Autoimmune 
reactions involving 
major organ (e.g., 
colitis, anemia, 
myocarditis, kidney)Life-threatening 
consequences; 
urgent 
intervention 
indicatedDeath
Definition : A disorder characterized by loss of function or tissue destruction of an organ or multiple organs, 
arising from humoral or cellular immune responses of the individual to his own tissue constituents.
Cytokine 
release 
syndromeFever with or 
without 
constitutional 
symptomsHypotension 
responding to 
fluids; hypoxia 
responding to 
<40% O2Hypotension 
managed with one 
pressor; hypoxia 
requiring ≥40% O2Life-threatening
consequences; 
pressor or 
ventilatory 
support 
indicatedDeath
Definition: A disorder characterized by fever, tachypnea, headache, tachycardia, hypotension, rash, and/or 
hypoxia caused by the release of cytokines.
Serum 
sicknessAsymptomatic; 
clinical or 
diagnostic 
observations 
only; intervention 
not indicatedModerate 
arthralgia; fever, 
rash, urticaria, 
antihistamines 
indicatedSevere arthralgia or 
arthritis; extensive 
rash; steroids or iv 
fluids indicatedLife-threatening 
consequences; 
pressor or 
ventilatory 
support 
indicatedDeath
Definition: disorder characterized by a delayed -type hypersensitivity reaction to foreign proteins derived from 
an animal serum. It occurs approximately six to twenty-one days following the administration of the foreign 
antigen. Symptoms include fever, arthralgias, myalgias, skin eruptions, lymphadenopathy, chest marked 
discomfort and dyspnea.
CTCAE=  common terminology criteria for adverse events; iv= intravenous
Depending on the observed grade of reaction, respective measures like general and specific 
drug treatment (e.g. ,anti-histamines) as well as temporary  or permanent stop of study  drug 
administration in the affected participant will be applied. I n case of a mild (grade 1 -2
according to CTCAE v5.0) hypersensitivity  reaction andan apparent s ymptoms relief ,the 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  48of 77
investigator may  decide to cautiously continue further dosing. If any hypersensitivity  
symptom re -occurs dosing will be stopped permanently .
In case of h ypersensitivity reactions of ≥ 3 dosing will be directly  stopped permanentl y.
Anaph ylaxis is strongly  suspected when respiratory  symptoms o r hypotension occurs within 
10 minutes of injection . All measures at site will be performed according the S2 Guideline for 
acute therap y and management of anaph ylaxis (31). 
8.3.9
AEs Requiring Submission to the CIAC
All deaths, and events suspected to be related to cardiovascu lar disease, or other arterial or 
venous thrombosis (including AVaccess thrombosis), but not limited to these and starting 
after signing informed consent (randomized participants only ), will be submitted to the CI AC 
for adjudication. Similarly , all bleeding events in randomized participants (except a 
participant’s normal/expected post- dialysis bleeding from AVaccess) will be submitted to the 
CIAC for adjudication. Details of the adjudication process will be described in the 
adjudication charter and additi onal study  specific guidance documents.
8.4 Treatment of Overdose
In the event of an overdose, the investigator should:
1.Contact the Medical Monitor immediately .
2.Closely  monitor the participant for an y AE/SAE and laboratory  abnormalities until 
study  intervention can no longer be detected s ystemically  (approx. 5 months).
3.Obtain blood sample sfor PK /PDanaly sis within 4 to10days and an additional one 
around 30 day sfrom the date of the last dose of study intervention ifnot alread y 
scheduled according to the study  protocol .
4.Document the quantit y of the excess dose as well as the duration of the overdose in the 
eCRF.
Decisions regarding dose interruptions or modifications will be made by  the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.5 Pharmacokinetics
For the investigation of systemic exposure of osocimab and its relationship with treatment 
effects, the plasma concentrations of osocimab will be determined at different time points 
using a sparse sampling approach in all participating subjects. Details about the collection, 
processing, storage and shipment of samples will be provided separatel y (e.g., in the 
laboratory  manual). Analy sis of samples from participants not treated with osocimab is 
optional. 
Blood samples will be collected at the time points indicated in the SoA (Section 1.3). PK 
samples obtained at additional tim e points based on the investigator’s discretion will not 
qualify  as a protocol deviation and will be used for PK analy sis as well. Deviations from the 
specified 
time points will be documented and taken into account for the PK anal ysis. Date and 
time of the PK sample collection and date and time of most recent study  drug administration
must be documented accuratel y in the eCRF .
PK samples will be anal yzed , using validated analy tical methods. Quality  control (QC) and 
calibration samples will be anal yzed concu rrently with study  samples. The results of 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  49of 77
calibration samples and QC samples will be reported in the Bioanal ytical Report which will 
be included in the clinical study  report ( CSR) for this study .
Pharmacokinetic and exposure- response analy sis might be per formed using population 
approaches (popPK and popPK/PD, e.g., b y non -linear mixed effect modeling). Anal ysis and 
report will be done under separate cover (see Section 6.3).
Exploratory  anal ysis of unbound osocimab or of the complex of 
osocimab bound to FXI(a) 
might be done if applicable.
8.6 Pharmacodynamics
For the investigation of the pharmacody namic response to osocimab and its relationship with 
treatment effects, pharmacody namic parameters detailed below will be determined at different 
time points using a sparse sampling approach in all participating subjects. Details about the 
collection, processing, storage and shipment of samples will be provided separately  (e.g.,in 
the 
laboratory  manual). Samples from participants not treated with osocimab will also be 
analyzed. 
Blood samples will be collected at the time points indicated in the SoA (Section 1.3). Blood
samples obtained at additional time points based on the investigator’s discretion will not 
qualify  as a protocol deviation and will be used for the PD analysis as well. Deviations from 
the specified time p oints will be documented and taken into account for the P Danaly sis. Date 
and time of the P D
sample collection and date and time of most recent stud y drug 
administration must be documented accuratel y in the eCRF.
For PD evaluation of osocimab the last sample taken prior to first drug administration will be 
defined as reference time point (i.e., will be assigned to a relative time of 00d00h00m). 
The actual date and time of blood sampling will be collected in the e CRF. All PD parameters 
will be measured using validated methods. Quality control and calibration samples will be 
analyzed concurrentl y with study  samples. For selected parameters, results of QC samples 
will be reported together with analy te concentrations in the Clinical Study  Report (CSR) for 
this study . Concentrations of the anal yte are calculated according to the method description. 
Detailed method descriptions of all PD methods will be filed with the CSR for this study . 
The following parameters will be used to assess the PD effects after administration of the 
investigational drug:
Main pharmacod ynamic parameters:
aPTT will be measured via the kaolin -trigger method (clotting assay ). Furthermore, 
the aPTT assay  will be conducted after in vitro -neutralizat ion of heparin in order to 
separate potential heparin effects from the PD effect of osocimab.
Factor XI activity  will be assessed with an aPTT-based coagulation test using FXI 
deficient plasma. Furthermore, the assay  will be conducted after in vitro- neutra lization 
of heparin in order to separate potential heparin effects from the PD effect of 
osocimab.
Other pharmacod ynamic parameters:
Activated Factor XIa activity  (AXIA) will be analy zed using a kaolin -trigger and a 
fluorogenic substrate readout .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  50of 77
Factor XI concentration will be anal yzed using an enzy me-linked immunosorbent
assay  (ELISA).
D-dimer will be analy zed using a particle -enhanced immunoturbidimetric method.
TAT (thrombin -antithrombin complex) will be analy zed using ELISA.
F1.2 will 
be anal yzed using ELISA.
The study  sponsors reserve the right not to conduct all or part of the above -mentioned 
analysis.
8.7 Genetics
Genetic as well as non -genetic analy ses may  be part of the biomarker investigations in this 
study . Genetic investigations may  be of an y kind, except for whole genome sequencing. See 
Section 8.8for details.
8.8 Biomarkers
Genetic as well as non -genetic biomarkers will be investigated. Biomarker anal yses might be 
performed optionall y and/or only in a subset of participants.
Exploratory bi omarkers : FVIII activity , FIX activity , FXII activity , von Willebrand factor 
antigen level, ristocetin cofactor (i.e. von Willebrand factor) activity .
Furthermore, some PD markers listed under Section 8.6might 
also be analyzed using 
alternative reagent/anal yzer manufacturers in order to assess potential s ystematic influences 
of the anal ysis technology . 
In addition to the biomarkers described above, further biomarkers related to, e.g., the mode of 
action or the safet y of the study intervention and similar drugs may be investigated. The same 
applies to further biomarkers deemed relevant to cardiovascular and renal diseases and 
associated health problems. These investigations may  include e.g., diagnostic, safet y, 
pharmacod ynamic, monitoring, or potentially  predictive biomarkers.
Timing
See SoA (Section 1.3) for planned time points of sample collection.
Sample handling and storage
Details on the collection, processing, storage, and shipment of biomarker samples will be
provided in separate docume nts (e.g., sample handling sheets or laboratory manual). Samples
may be stored for a maximum of 15 y ears (or according to local regulations) following the
end of the stud y at a facility  selected by  the sponsor to enable further anal yses.
Reporting
Some of 
the results of biomarker investigations may be reported separately (e.g. ,in a 
biomarker evaluation report).
8.9 Immunogenicity Assessments
The development of anti-drug antibodies ( ADAs ) to osocimab will be investigated in plasma
samples from all participants taken at the time points indicated in the SoA (Section 1.3). 
Measurement of ADAs will be done batch -wise only  as there is no expected direct impact 
on
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  51of 77
participant s´ safet y in this respective stud y setting. In case of any  hypersensitive AE of life -
threatening consequences the ADA measurement will be carried out at short notice.
Plasma samples will be screened for ADAs to osocimab and the result as wel l as the titer of 
confirmed positive ADA samples will be reported. ADA positive samples will be further 
characterized for their ability  to neutralize the activity  of osocima b(i.e. Neutralizing antibody  
(NAB) analy sis). Other analy ses may  be performed to further characterize the 
immunogenicit y ofosocimab .Anal ysis of samples from participants not treated with 
osocimab is optional.
Further details on collection, labeling, storage, and shipping of samples are provided in a 
separate laboratory  manual. Immunogenicity samples will be anal yzed using validated 
analytical methods. Positive controls will be analyzed concurrently with study  samples. The 
results of samples and positive control samples will be reported in the Bioanaly tical Report 
which will be includ ed in the CSR for this study .
8.10 Health Economics OR Medical Resource Utilization and Health 
Economics 
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study . 
9. Statistical Considerations 
9.1 Statistical Hyp otheses
The primary  objective of this study  is a qualitative assessment of safet y. All anal yses are 
performed in a descriptive manner and thus no formal hy pothesis is defined. 
9.2 Sample Size Determination 
Assuming 25% screen failure proportion as based on historic operational experience , 
approximately  800 participants will be screened to achieve an estimated total of
approximately 600 participants randomly  assigned to study  intervention . Of those, 
555
participants are expected to complete the main treatment period assuming a true incidence rate 
of 15 participants with LTFU (lost to follow -up) ( including e.g., withdrawal of consent) per 
100 participant- years across all groups.
As aparticipant will be evaluated o nce he was randomized and received at least one dose of 
study  intervention , the number of evaluable and randomized participants can be assumed to be 
similar.
In case that the observed overall incidence rate of participants with LTFU after the 400th
participant is significantly  higher th an ex pected, the number of randomized participants may  
be increased (max. of 7 50participants) to ensure a sufficient number of participants 
completing the main treatment period.
As all anal yses will be performed in a descriptive manner, no statistically  driven sample size 
calculation was performed.
The expected 90% confidence interval for the hazard ratio of the primary  safet y outcome is 
given b y [0.57; 2.28], assuming  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  52of 77
1.a true incidence rate of 10 participants with a major or clinically- relevant non -major 
bleeding event (in alignment with ISTHguidelines) per 100 participant- years in the 
placebo group (see below for definition)
2. a true hazard ratio of 1.0 (i.e. no change in relative risk) in b oth osocimab groups as 
compared to placebo
3.6 months of treatment with a true incidence rate of 15 participants with LTFU per 100 
participant -years across all groups.
The corresponding expected 90% confidence interval for the hazard ratio of the primary  
efficacy  outcome is given by  [0.44; 1.53]. while additionally  assuming  
1.a true incidence rate of 1 3 participants with a primary  efficacy  outcome per 100 
participant -years in the placebo group .
2.
a true hazard ratio of 0.75 in both osocimab groups as compared to placebo
For details on screen failures see Section 5.4.
9.3 Populations for Analyses 
The populations are defined in Table 
9–1.
Table 9
–1: Populations for Analyses
Population Description
Enrolled All participants who sign the ICF
Full analysis set All participants randomly assigned to study intervention.
Safety All participants randomly assigned to study intervention who
received at least 1 dose of study intervention. Participants will be 
analyzed according to the intervention they actually received.
Pharmacokinetic analysis set All osocimab -treated participants with at least 1 PK sample in 
accordance with the PK sampling schedule (Section 1.3and8.5) 
and without deviation from the protocol that would interfere with the 
evalu ation of the PK data will be included in the PK analy sis.
Pharmacodynamic analy sisset All participants with at least 1 PD sample in accordance with the PD 
sampling schedule and without deviation from the protocol that 
would interfere with the evaluation of the P Ddata will be included in 
the PD analysis.
Listing only set All participants who signed consent but are not randomized.
Abbreviations: ICF = Informed consent form , PD =pharmacodynamic(s), PK =pharmacokinetic(s)
9.4 Statistical Analyses
The statistical anal ysis plan will be finalized prior to FPFV (first patient first visit) and it will 
include a more technical and detailed description of the statistical anal yses described in this 
section. This section is a summary  of the planned statistical analy ses of the most important 
endpoints including primary  and key secondary  endpoints.
9.4.1 General 
Considerations
The statistical anal ysis will be performed using SAS; the version used will be specified in the 
statistical analy sis plan. In general, all variables including demography  and baseline 
characteristics will be summarized by treatment group and b y providing frequency tables for 
categorical variables and summary statistics for continuous variables. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  53of 77
For the primary  analysis, only  the main treatment period will be considered . The partial data
of a participant’s extended treatment period up until primary  completion may be presented in 
separate tables. Furthermore, the primary  anal ysis will be performed on the safety analysis set 
in accordance with the “ population” attribute of the primary  estimand.
In general, participants receiving placebo in either 
the low- dose or the high- dose cohort will 
be analyzed in a pooled manner . This group will be referred to asplacebo group. The group of 
participants receiving osocimab in the high dose cohort ( or low dose cohort) will be referred 
to as high dose ( or low dose osocimab) group.
Where appropriate, the osocimab groups will be additionally  display ed in a pooled man ner.
9.4.2 Primary Endpoints
Theprimary  safet y analysis is a descriptive time to first primary  safety event ( for both 
endpoints: composite of major and clinicall y-relevant non -major bleeding events [in 
alignment with ISTH guidelines] and moderate and severe AEs and SAEs ). 
The primary  objective is to assess the safet y under an osocimab concentration which is 
expected to be maintained during a chronic treatment. Thus the aim it to assess the response to 
treatment while the participant is
alive (intercurrent event “death”) and 
exposed to study  intervention (intercurrent event “premature discontinuation of 
treatment”).
Therefore, the time to the first primary  safety  event is defined as time from first dose of study  
intervention to the first event of the endpoint of interest up until 30 day s after last study  
intervention in the main treatment period. The time under risk for a participant without a 
primary  safety  event will be censored at the date of the EOMT visit, or 30 day s after study  
intervention discontinuation, or at the last date data was collected for a participant (e.g. ,for 
participants lost to follow -up) in the main treatment period, whatever occurs first.
The cumulative incidence risk for the primary  safety  event together with its confidence 
interval will be estimated. Each of the osocimab groups will be compared to the placebo 
group using two- sided log -rank tests at a t ype I error rate of α=10%. Due to the explorative 
nature of these anal yses, no multiplicity  adjustment will be done.
Hazard ratios comparing each of the osocimab groups with the placebo group and 
corresponding 90% (and 95%) confidence intervals will be estimated, as appropriate, from 
Cox proportional hazards models.
Hazard ratio, relative risk reduction (RRR; RRR = 10 0 × [1 –hazard ratio]%), and 
corresponding 2-sided 90% and 95% confidence intervals comparing each of the osocimab 
groups with the placebo group will be estimated based on two separate Cox proportional 
hazards models. Censoring will be assumed independent of the randomized group assignment.
For the anal ysis of the primary  endpoint in this study , the hazard function h(t) is the chance 
that an individual experiences an event of the primary  safety  outcome in the next instant in 
time, given that the individual has not had such an event up to time t. For example, for the 
comparison of the osocimab high dose group with the placebo group, the corresponding Cox 
proportional hazards model can be described by  the following equation:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  54of 77
h(t,x i) = h 0(t) exp( β x i),
where 
h(.) hazard function for primary  safety  outcome, as a function of time and participant’s 
covariates
h0(.) unspecified underly ing baseline hazard function for primary  safet y outcome; hazard 
of an individual with x i = 0
t time (in day s) relative to the date of first stud y intervention
xi treatment group of participant i
(0 corresponds to “placebo group” and
1 corresponds to “osocimab high dose group”)
β unknown parameter (to be estimated); hazard ratio = exp(β)
Only  events that started after the first dos e of study treatment and during the main treatment 
period are consider ed for the primary  analy sis. Events that occurred during the pre -treatment 
period will be display ed in an exploratory  manner.
9.4.3
Secondary Endpoints
The a ctivated partial thromboplastin tim e (aPTT) andFXIa activity  at trough levels after 6 
months will be analy zed as ratio to baseline by providing the mean and median, together with 
the standard deviation and quantiles, respectivel y.
The exploratory  composite efficacy  endpoint will be analyzedusing a time to event anal ysis 
similarly  to the primary  safet y endpoint s. Thus, the descriptive anal ysis focuses on estimating 
the efficacy  under an osocimab concentration which is expected to be maintained during a 
chronic treatment.
Only  events that started after the first dose of study  treatment and during the main treatment 
period are considered for the primary  analy sis. Events that occurred during the pre -treatment 
period will be display ed in an exploratory  manner.
The endpoint of thrombosis of the arterio
-venous grafts or fistulas will be handled similar .
9.4.4 Other Analyses
The difference in the median of SQCSs during main treatment p eriod between each of the 
osocimab groups and the placebo group will be display ed together with the corresponding 
90% (and 95%) confidence intervals based on a T -test.
Furthermore, the difference of the proportion of hemodialy sis sessions with adequate 
anticoagulation during main treatment period between each of the osocimab groups and the 
placebo group will be summarized with the corresponding 90% (and 95%) confidence 
intervals based on a proportion test.
The difference in the median of AV access bleeding score during main treatment p eriod
betwee n each of the osocimab groups and the placebo group will be displayed with the 
corresponding 90% (and 95%) confidence intervals based on a T -test.
Furthermore, the difference of the proportion of hemodialy sis sessions with no AV access 
bleeding during main treatment period between each of the osocimab groups and the placebo 
group will be summarized with the corresponding 90% (and 95%) confidence intervals based 
on a proportion test.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  55of 77
Both the safety  and efficacy  analy ses will be repeated based on the full da ta to also include 
event s that occurred during the extension treatment period and during the follow- up period.
PK variables
For the investigation of PK, the plasma concentrations of osocimab will be determined at the 
times given in Section 1.3using a sparse sampling approach.
The data processing and the statistical anal ysis will be performed in accordance with the 
sponsor’s current guidelines.
Osocimab concentrations will be summarized by  visit, separated according to actual dose
cohort . Descriptive statistics of plasma concentrations [geometric mean and percent 
coefficient of variation (%CV), arithmetic mean and %CV, median and range] will be 
presented by treatment group and time in tabular form. Means at an y time will only  be 
calculated if at least 2/3 of the individual data were measured and were above the lower limit 
of quantification (LLOQ). For the calculation of the mean value, a data point below LLOQ 
will be substituted by  one half of this limit. I n tables showing mean values, where values 
below LLOQ are included in the calculation of mean values, these means will be marked.
Further details will be specified in the statistical analy sis plan.
Pharm acokinetic and exposure
-response analy sis using population approaches (popPK and 
popPK/PD, e.g., b y non -linear mixed effect modeling) will be reported under separate cover, 
if applicable.
PD variables
Results of the additional pharmacod ynamics parameter will be display ed utilizing appropriate 
summary  statistics and figures. The parameters will be described b y the following summary 
statistics: arithmetic mean, standard deviation, median, minimum and maximum. These 
summary  statistics will be presented by  actu al dose group for the original data as well as for 
the absolute and relative changes from baseline as ratio to baseline . In addition, for each 
participant the maximum and minimum relative change from baseline will be determined and 
presented b y appropriate summary  statistics and figure.
The exploratory  PD marker results may  be reported separatel y.
9.5 Interim Analyses
No formal interim anal ysis is planned.
The primary  anal ysis will be performed after all participants have completed the main 
treatment period (primary  completion) . Afull analy sis will be performed after the last 
participant has completed the 
follow -up of 4 month s (study  completion).
Furthermore, the DMC will frequently  review safety  data to ensure the safety  of the 
participants in the ongoing study . The required tables and listings will be created by an 
independent Statistical Analy sis Center ( SAC ).
9.6 Data Monitoring Committee (DMC)
A DMC willfrequentl y review safet y data toensure the safet y of the participants in the 
ongoing stud y.
For details on DMC refer to Section 10.1.5.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  56of 77
10. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study  conduct; the investigator may  not modify  or alter the procedures described in this 
protocol. Modifications to the study protocol will not be implemented by either the sponsor or 
the investigator without agreement b y both parties. However, the investigator or the sponsor 
may implement a deviation from, or a change of the protocol to eliminate an immediate 
hazard(s) to the trial participant s without prior IE C/IRB/sponsor approval/favorable opinion. 
As soon as possible, the implemented deviation or change, the reasons for it and if appropriate 
the proposed protocol amendment should be submitted to the IEC/IRB/head of medical 
institution/sponsor. Any  deviations from the protocol must be explained and documented b y 
the investigator .
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
Consensus ethical principles derived from international gui delines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
Applicable ICH Good Clinical Practice (GCP) Guidelines
Applicable laws and regulations
The protocol, prot ocol amendments, I CF, Investigator Brochure, and other relevant 
documents ( e.g., advertisements) must be submitted to an IRB/IEC by  the investigator 
and reviewed and approved by  the IRB/IEC before the study  is initiated. 
Any amendments to the protocol wil l require IRB/I EC approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  participants. Any substantial modification of 
the protocol will be submitted to the competent autho rities as substanti al amendments 
for approval, in a ccordance with ICH Good Clinical Practice and national and 
international regulations.
The investigator will be responsible for the following:
1. Providing written summaries of the status of the study  to the I RB/IEC annually  
or more frequentl y in accordance with the requirements, policies, and 
procedures established by the IRB/IEC
2. Notify ing the IRB/IEC of SAEs or other significant safet y findings as required 
by
 IRB/IEC procedures
3. Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of ICH guidelines, the I RB/IEC, and all other applicable local 
regulations
10.1.2 Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial 
information as requested to allow the sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  57of 77
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions 
regarding the stud y. 
Participants must be informed that their participation is volunta ry. Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50 (Code of Federal Regulations) , 
local regulations, ICH guidelines, Health Insurance Portability  and Accountability  Act 
(HIPAA) requirements, where applicable, and the I RB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The authorized person obtaining the informed consent must also 
sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the participant’s legall y 
authorized representative. 
The signed informed consent is to remain in the I nvestigator Site File or, if locally  required, in 
the participant ’s note/file of the medical institution. 
Participants who are re -screened are required to sign a new ICF.
10.1.4 Data Protection
Participants will be assigned a unique identifier by  the sponsor. Any  participant 
records or datasets that are transferred to the sponsor will contain the identi fier only ; 
participant names or an y information which would make the participant identifiable 
will not be transferred.
The participant must be informed that his/her personal study -related data will be used 
by the sponsor in accordance with local data prote ction law. The level of disclosure 
must also be explained to the participant who will be required to give consent for their 
data to be used as described in the informed consent
The participant must be informed that his/her medical records may  be examined by 
Clinical Quality  Assurance auditors or other authorized personnel appointed by  the 
sponsor, by  appropriate IRB/IEC members, and by  inspectors from regulatory  
authorities.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  58of 77
10.1.5 Committees Structure
Three independent committees will be est ablished in order to ensure a high -standard stud y 
conduct according to GCP, aiming to achieve ultimate integrity , consistency, and high quality  
data, and most importantly ensure the safet y of the participants enrolled in the study. The 
committees are:
Steering Committee (SC) : 
The SC will advise on all scientific aspects of the study  and it will ensure that study  execution 
and management of the study  are of the highest quality . The Steering committee will consist 
of: External key  experts in the field of 
nephrology , cardiology  and hematology  and sponsor 
representatives. Further details can be found in the SC charter.
Data Monitoring Committee (DMC): 
The primary  role of the DMC is to 
frequently review the safety  data and ensure the safet y of 
the participan ts in the ongoing study  including unblinded data if deemed necessary . The DMC 
will consist of members who have recognized clinical expertise or expertise in biostatistics
and who are not members of the steering committee, or involved as investigators or ot herwise 
in the trial. Further details can be found in the DMC charter.
Central Independent Adjudication Committee (CIAC):
The central independent adjudication committee is blinded to treatment allocation and dose 
cohort 
and will objectively  assess the saf ety and efficacy  outcomes of the study  and may 
convene on an ad -hoc basis for timely  assessment. Further details will be found in the CI AC 
charter.
10.1.6 Dissemination of Clinical Study Data
Result Summaries of Bayer's sponsored clinical trials in drug developme nt Phases 2, 3and 4
and Phase 
1studies in patients are provided in the Bay er Trial Finder application after 
marketing authorization approval in line with the position of the global pharmaceutical 
industry  associations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition results of clinical drug 
trials will be provided on the publicly  funded website www.ClinicalTrials.gov and European 
Union ( EU) Clinical Trials Register in line with the applicable regulations.
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical trials 
in patients for medicines and indications approved in the United States (US) and EU on or 
after January  01, 2014 as necessary  for conducting legitimate research. 
All Bay er-sponsored clinical trials are considered for publication in the scientific literature 
irrespective of whether the results of the clinical trials are positive or negative.
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (e.g., laboratory data). The 
investigator is responsible for verify ing that data entries are accurate and correct by  
physicall y or electronically  signing the CRF. 
The investigator must maintain accurate documentation (source data) that supports the 
information 
entered in the CRF. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  59of 77
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Monitoring details describing strategy  (e.g., risk -based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
The sponsor assumes accountability  for actions delegated to other individuals ( e.g.,
Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of p articipants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICFs, pe rtaining to the conduct of this study  
must be retained b y the investigator for 15years after study  completion unless local 
regulations or institutional policies require a longer retention period. No records may  
be destro yed during the retention period wit
hout the written approval of the sponsor. 
No records may  be transferred to another location or part y without written notification 
to the sponsor. 
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and 
substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source documents or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be found in the source data location list .
10.1.9 Study an d Site Start and Closure
The study  start date is the date on which the first clinical study  site is open edfor recruitment 
of participants.
The first act of recruitment is the First Patient First Visit for whole study .
The sponsor designee reserves the right to close the study  site or terminate the study  at any  
time for an y reason at the sole discretion of the sponsor. Study  sites will be closed upon study  
completion. A study  site is considered closed when all required documents and study  supplies 
have been collected and a study -site closure visit has been performed.
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  60of 77
Reasons for the ear ly closure of a stud y site b y the sponsor or investigator may include but are 
not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of participants by  the investigator
Discontinuation of further study  intervention development
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
investigators, the IECs/IRBs, the regulatory aut horities, and any  contract research 
organization(s) used in the study  of the reason for termination or suspension, as specified b y 
the applicable regulatory  requirements. The investigator shall promptly  inform the subject and 
should assure appropriate subj ect therap y and/or follow -up
10.1.10 Publication Policy
The results of this study  may  be published or presented at scientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allow s the sponsor to protect proprietary  information and to 
provide comments. 
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support public ation of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordinating investigator will be designated b y mutual 
agreement.
Authorship will be determined by  mutual agreement and in line with I nternational 
Committe e of Medical Journal Editors authorship requirements.
In addition the sponsor recognizes the right of the investigator to publish the results 
upon completion of the study . However, the investigator, whilst free to utilize study  
data derived from his/her ce nter for scientific purposes, must obtain written consent of 
the sponsor on the intended publication manuscript before its submission. To this end, 
the investigator must send a draft of the publication manuscript to the sponsor within a 
time period specified in the contract. The sponsor will review the manuscript promptly  
and will discuss its content with the investigator to reach a mutually  agreeable final 
manuscript.
10.2 Appendix 2: Clinical Laboratory Tests
For details on the sampling scheme, please refer to Section 1.3 Schedule of Activities (SoA).
The tests detailed in Table 10–1 will be mostly  performed b y the central laboratory. 
Central laboratory  results may  not be available in time for necessary  medical 
decisions. Therefore, local laboratory  tests are performed a ccording to usual patient 
care schemes at the site, per decision of the investigator/treating phy sicians. If SAEs 
are triggered b y local laboratory  results the respective findings must be documented in 
the eCRF.
Protocol -
specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  61of 77
Additional tests may  be performed at an y time during the stud y as determined 
necessary  bythe investigator or required by  local regulations.
Pregnancy  Testing
Biomarkers (for details see Section 8.8) 
Pharmacod ynamic and pharmacokinetic parameters as well as safet y laboratory parameters 
will be anal yzed by central laboratories. The names and the addresses of the central laboratory  
service providers can be found in the documentation supplied by  the vendor (laboratory  
manual).
During the s
creening visit, only  local laboratory  samples will be assessed to check the 
eligibility  of the patient. 
At least allparameters listed in Table 10–1 under screening tests at local laboratory must be 
assessed at the 
screening visit and entered in the eCRF to check the patient’s eligibility for the 
study .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  62of 77
Table 10–1 : Protocol -required Laboratory Assessments
Laboratory 
AssessmentsParameters
Central laboratory 
HematologyHemoglobin
Hematocrit
Red blood cell (RBC) count (MCV, MCH, MCHC , %reticulocytes)
Platelet count
White blood cell (W BC) count with d ifferential (neutrophils , lymphocytes , 
monocy tes, eosinophils , basophils )
Clinical c hemistry Alanine aminotransferase (ALT)
Albumin
Alkaline phosphatase
Amylase
Aspartate aminotransferase (AST)
Bicarbonate
Bilirubin, total and direct
Blood urea nitrogen (BUN)
Calcium
Chloride
Cholesterol [high density lipoprotein (HDL), low density lipoprotein 
(LDL), total]
Creatinine
Creatine kinase (CK)
Glucose
Gamma glutam yl transpeptidase (GGT)
high-sensitivity C -reactive protein (hs -CRP)
Highly sensitive serum beta human chorionic gonadotr opin (βh CG)
Iron s aturation and ferritin
Lactate dehydrogenase (LDH)
Lipase
Magnesium
Parathyroid hormone (PTH)
Phosphorus
Potassium
Serum glutam ic-oxaloacetic transaminase (SGOT)
Serum glutam ic-pyruvic transaminase (SGPT)
Sodium
Total protein
Triglycerides
Troponin
Uric acid
Coagulation parameters should not be reviewed by blinded staff.
CoagulationActivated partial thromboplastin time (aPTT)
Prothrombin time (PT), seconds and INR (International normalized 
ratio)
D-Dimer
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  63of 77
Laboratory 
AssessmentsParameters
Local laborato ry
Screening TestsHighly sensitive s erum beta human chorionic gonadotropin ( βhCG) 
pregnancy test (as needed for women of childbearing potential)
All study -required laboratory assessments for eligibility will be performed 
by a local laboratory:
Activated partial thromboplastin time (aPTT)
Prothrombin time (PT)
Bilirubin (direct, total)
Alanine aminotransferase (ALT)
Hemoglobin
Platelet count
The results of each test must be entered into the e lectronic case report 
form.
NOTES:
Please note that if screening parameters are available as part of routine medical practice , these 
are not required to be repeated as long as they were measured within 14 days of screening and 
meet the thresho ldsdefined in the in -/exclusion criteria.
Abbreviations: MCH =mean corpuscular/cellular hemoglobin, MCHC =mean corpuscular/cellular hemoglobin 
concentration, MCV =mean corpuscular/cell volume
Investigators must document their review of each laboratory  safet y report.
Coagulation parameter sthat could unblind the study  will not be reported to investigative sites 
or other blinded personnel if not medically  required .
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE
AE De finition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
whether or not considered related to the stud y intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) whether or 
notassociated with the use of study  intervention.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments ( e.g.,ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically  
significant in the medical and scientific judgment of the investigator (i.e., not related 
to progression of underl ying d isease).
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  64of 77
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
The signs, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfil the definition of an AE or SAE. Also, “lack of 
efficacy ” or “failure of expected pharmacological action” also constitutes an AE or 
SAE.
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure ( e.g., endoscopy , appendectom y): the condition that 
leads to the procedure is th
e AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study  that do not worsen.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e .g., hospitalization for signs/sy mptoms of the disease under study , death 
due to progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in 
which the participant was at risk of death at the time of the event. It does not 
refer to an event, which hy pothetically  might have caused death, if it were more 
severe.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  65of 77
c. Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant ha s been detained 
(usually  involving at least an overnight stay ) at the hospital or emergency  ward 
for observation and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complications that occur during 
hospital ization are AEs. If a complication prolongs hospitalization or fulfills any  
other serious criteria, the event is serious. When in doubt as to whether 
“hospitalization” occurred or was necessary , the AE should be considered 
serious.
Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.
d. Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to 
conduct normal life functi ons.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma ( e.g., sprained ankle) which may  interfere with 
or prevent eve ryday life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize t he participant or may require medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsions that do not result in hospitalization, or development of 
drug dependency  or drug abuse.
10.3.3 Recording and Follow -Up of AE and/or SAE
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation ( e.g.,hospital progress notes, laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE/SAE informa tion in the eCRF.
It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to sponsor in lieu of completion of the AE/SAE eCRF page.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  66of 77
There may  be instances when copies of medical records for certain cases are 
reque sted b y sponsor and CI AC. In this case, all participant identifiers, with the 
exception of the participant number, will be redacted on the copies of the medical 
records before submission to sponsor .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed as 
severe should not be confused with an SAE. Se vere is a category  utilized for rating 
the intensity  of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT wh en it is rated as severe.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  67of 77
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the I nvestigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may  be situations in which an SAE has occurred and the investigato r has 
minimal information to include in the initial report to thesponsor ’s PV . However, it 
is very important that the investigator always make an assessment of causality 
for every event before the initial transmission of the SAE data to sponsor .
The inves tigator may  change his/her opinion of causality  in light of follow -up 
information and se nd an SAE f ollow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirement s.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested b y sponsor 
to elucidate the nature and/or causalit y of the AE or SAE as fully  as possible. This 
may include additional laboratory  tests or investigations, histopathological 
examinations, or consultation with other health care professionals.
If a participant dies during participation in the study or during a recognized follo w-
up period, the investigator will provide the CIAC with a cop y of an y post - mortem 
findings including histopathology . 
New or updated information will be recorded in the originally  completed eCRF.
The investigator will submit any  updated SAE data to thesponsor ’s PV within 24 
hours of receipt of the information.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  68of 77
10.3.4 Reporting of SAEs
SAE Reporting to the Sponsor via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to sponsor will be the electronic data 
collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the study  is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to the sponsor’s medical monitor by telephone.
Contacts for SAE reporting can be found in Investigator Site File .
SAE Reporting to Sponsor via Paper CRF
Email transmission of the SAE paper CRF is the preferred method to transmit this 
information to the sponsor .
In rare circumstances and if email transmission is not feasible, notification by  
telephone is acceptable with a cop y of the SAE data collection tool sent by overnight 
mail or courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within t he designated reporting time frames.
Contacts for SAE reporting can be found in the Investigator Site File.
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post- menopausal 
unless permanentl y sterile (see below) .
If fertility  is unclear ( e.g., amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study  intervention, additional evaluation should be 
considered.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  69of 77
Women in the following categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpingectomy
Documented bilateral ooph orectom y
For individuals with permanent infertility  due to an alternate medical cause other than the 
above, ( e.g., mullerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s: review of the participant’s 
medical records, medical examination, or medical history  interview.
3.Postmenopausal female
A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.
A high fo llicle stimulating hormone (FSH) level in the postmenopausal 
range may  be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therap y (HRT). 
However, in the absence of 12 months of amenorrhea, confirmati on with 
more than one FSH measurement is required. 
Females on HRT and whose menopausal status is in doubt will be required to use 
one of the non -estrogen hormonal highl y effective contraception methods if they 
wish to continue their HRT during the stud y. Otherwise, they  must discontinue 
HRT to allow confirmation of postmenopausal status before study  enrollment.
Contraception Guidance:
Women of childbearing potential with their partner must agree to use a highly effective 
contraception method from signing informed consent until approx. 150 days (due to long half -
life with only  monthly  administration) after last study  intervention .
If engaged in sexual activity  with child -bearing potential partner, male participant
s with their 
female par tner must use highl y effective contraception from signing informed consent until 
approx. 150 day s (due to long half -life with only  monthly  administration) after last study  
intervention . 
Highl y effective contraception methods are for example: 
History  of surgical sterilization (male participant or female partner)
Female partner uses hormonal contraception or intrauterine contraception/device
Sexual abstinence
Male participants with partners that are pregnant must use condoms as contraception to ensure 
that the fetus does not get in contact with sperm fluid in case it may  contain osocimab .Also 
male participants with female partners who are breast feeding must use condoms.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  70of 77
Collection of Pregnancy Information:
Male participants with partners who become pregnant 
The investigator will attempt to collect pregnancy  information on any  male 
participant’s female partner who becomes pregnant while the male participant is in 
this study . This applies only  to male participants who receive stud y inter vention, after 
up to the last follow -up visit (5 months after the last intervention is given).
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the approp riate 
form and submit it to the sponsor within 24 hours of learning of the partner’s 
pregnancy . The female partner will also be followed to determine the outcome of the 
pregnancy . Information on the status of the mother and child will be forwarded to the 
sponsor. Generally , the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery  date. Any  termination of the pregnancy  will be reported regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.
Fem ale participants who become pregnant 
The investigator will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. The initial information will be 
recorded on the appropriate form and submitted to th e sponsor within 24 hours of 
learning of a participant's pregnancy . 
The participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on the participant and the neonate and 
the information will be forwarded to the sponsor. Generally , follow -up will not be 
required for longer than 6 to 8 weeks bey ond the estimated delivery  date. Any  
termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indicat ion for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy for medical reasons will be 
reported as an AE or SAE. 
A spontaneous abortion (occurring at <22 weeks gestational age) or still birth 
(occurring at >22 weeks gestational age) is always considered to be an SAE and 
will be reported as such. 
Any post -study  pregnancy  related SAE considered reasonabl
y related to the study  
intervention by  the investigator will be r eported to the sponsor as described in 
Section 8.3.4. While the investigator is not obligated to activel y seek this information 
in former stud y participants, he or she may  learn of an SAE through spontaneous 
reporting. 
Any female participant who 
becomes pregnant while participating in the study  will 
discontinue study  intervention.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  71of 77
10.5 Appendix 5: Genetics
Genetic as well as non -genetic analy ses will be part of the biomarker investigations in this 
study . See S ection 8.8for details.
Details on sample handling will be provided separately .
10.6 Appendix 6: Country -specific Requirements 
China:
Study  participating sites in China are excluded from all PD and biomarker sampling 
and analyses.
German y:
The exclusion of participants, who are committed to an institution by  virtue of an 
order issued either b y the judicial or the administrative authorities.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  72of 77
10.7 Appendix 7: Abbreviations and Definitions
ADA Anti-drug antibodies
AE Adverse event
AESI Adverse event of s pecial interest
ALT Alanine aminotransferase
aPTT Activated partial t hromboplastin time
ASA Acet ylsalicy licacid
ASO Antisense oligonucleotide
AST Aspartate aminotransferase
AV Arteriovenous
AXIA Activated Factor XIa activity
BUN Blood urea nitrogen
BW Body weight
βhCG Beta h uman chorionic gonadotropin
CAD Coronary  artery  disease
CFR Code of Federal Regulations
CIAC Central Independent Adjudication Committee
CIOMS Council for International Organizations of Medical Sciences
CK Creatine kinase
CKD Chronic kidney  disease
CONSORT Consolidated Standards of Reporting Trials
CRF Case report form
CRN MB Clinically relevant non- major bleeding
CSR Clinical study  report
CTCAE Common Terminology  Criteria for Adverse Events
CV Cardiovascular
CYP Cytochrome P450
DMC Data Monitoring Committee
e.g. exempli gratia, for example 
ECG Electrocardiogram
eCRF Electronic case report form
ED Early discontinuation
ELISA Enzyme-linked immunosorbent assay
EOET End of extension treatment pe riod
EOMT End of main treatment pe riod
ESRD End- stage renal disease
EU European Union
EudraCT European Clinical Trials Database
FEIBA Factor eight inhibitor bypass activity
FFP Fresh frozen plasma
FPFV First patient first visit
FSH Follicle stimulating hormone
FVIIa Factor VIIa
FVIII Factor VIII
FXI Factor XI
FXIa Factor XIa
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  73of 77
FXII Factor XII
GCP Good Clinical Practice
GGT Gamma glutamy l transpeptidase
Hb Hemoglobin
HDL High densit y lipoprotein
HIPAA Health Insurance Portability  and Accountability  Act
HRT Hormonal replacement therap y
hs-CRP high-sensitivity  C-reactive protein
i.e. id est ,that is
IB Investigator’s Brochure
ICF Informed consent form
ICH International Council for Harmonization
IEC Independent Ethics Committee
IgG1 Immunoglobulin G1
IMP Investigational medical product
IND Investigational new drug
INN International non -proprietary  name
INR International normalized ratio
IRB Institutional Review Board
ISTH International Societ y on Thrombosis and Hemostasis
iv Intravenous(l y)
IWRS Interactive web response system
LD Loading dose
LDH Lactate deh ydrogenase
LDL Low density  lipoprotein
LLOQ Lower limit of quantification
LMWH Low molecular weight heparin
LTFU Lost to follow -up
MACE Major adverse cardiovascular event
MB Major bleeding
MCH Mean corpuscular/cellular hemoglobin
MCHC Mean corpuscular/cellular hemoglobin concentration
MCV Mean corpuscular/cell volume
MD Maintenance/ monthl y dose
MedDRA Medical Dictionary  for Regulatory  Activities
MI Myocardial infarction
MRI Magnetic r esonance imaging
NA Not applicable
NAB Neutralizing antibodies
NYHA New York Heart Association
PAD Peripheral artery  disease
PCC Prothrombin complex concentrate
PD Pharmacod ynamic(s)
PE Pulmonary  embolism
PID Participant identification code
PK Pharmacokinetic(s)
popPK Population PK
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  74of 77
PRIND Prolonged reversible ischemic neurological deficit
PT Prothrombin t ime
PTH Parathy roid hormone
pts Participants
PV Pharmacovigilance
QC Quality  control
q.i.d Quater in die, four time s a day
R Randomization
RBC Red blood cell
RCTs Randomized clinical trials
RND Randomization
RRR Relative risk reduction
RRT Renal replacement therapy
SAC Statistical Analy sis Center
SAE Serious adverse event
SAS Statistical Analysis Software
sc Subcutaneous(l y)
SC Steering Committee
SE Systemic embolism
SGOT Serum Glutamic -Oxaloacetic Transaminase
SGPT Serum Glutamic -Pyruvic Transaminase
SoA Schedule of activities
SOP Standard operating procedure
SQCS Semi-quantitative clotting score
SUSAR Suspected unexpected serious adverse reactions
TAT Thrombin -antithrombin complex
TE Thromboembolic
TF Tissue factor
TKA Total knee arthroplast y
UFH Unfractionated heparin
ULN Upper limit of normal
URR Urea reduction ratio
V Visit
VTE Venous thromboembolism
vWF Von Willebrand factor
WBC White blood cell (count)
WHO World Health Organization
WOCBP Woman of childbearing potential
%CV Percent coefficient of variation
Month equals 30 days ±3 day swhen referring to monthly  dosing
Hemodialy sis the term hemodial ysis includes hemodiafiltration
Outcom e Assessor the term Outcome Assessor includes CIAC and DMC
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  75of 77
11. References
1. WHO. World Health Organization Cardiovascular diseases (CVDs) Fact Sheet 
(available from: httpp:// www.who.int/mediacentre/factsheets/fs317/en/ . 2018.
2. United States Renal Data Sy stem. 2015 USRDS annual data report: Epidemiology  of 
Kidney  Disease in the United States. National Institutes of Health, National I nstitute 
of Diabetes and Digestive and Kidney  Diseases, Bethesda, MD, . 2015.
3. Eknoy an G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of 
dialy sis dose and membrane flux in maintenance hemodialy sis. N Engl J Med. 
2002;347(25):2010 -
9.
4. Foley  RN, Parf rey PS, Sarnak MJ. Clinical epidemiology  of cardiovascular disease in 
chronic renal disease. Am J Kidney  Dis. 1998;32(5 Suppl 3):S112-9.
5. Bhatti NK, Karimi Galougahi K, Paz Y, Nazif T, Moses JW, L eon MB, et al. 
Diagnosis and Management of Cardiovascular Disease in Advanced and End- Stage 
Renal Disease. J Am Heart Assoc. 2016;5(8):e003648.
6. O'Hare AM, Bacchetti P, Segal M, Hsu CY, Johansen KL, Dial ysis M, et al. Factors 
associated with future amputation among patients undergoing hemodial ysis: results 
from the Dial ysis Morbidity  and Mortalit y Study Waves 3 and 4. Am J Kidney Dis. 
2003;41(1):162 -70.
7. O'Hare AM, Glidden DV, Fox CS, Hsu CY. High prevalence of peripheral arterial 
disease in persons with renal insufficiency : results from the National Health an d 
Nutrition Examination Survey  1999-2000. Circulation. 2004;109(3):320 - 3.
8. Reinecke H, Brand E, Mesters R, Schabitz WR, Fisher M, Pavenstadt H, et al. 
Dilemmas in the management of atrial fibrillation in chronic kidney  disease. J Am Soc 
Nephrol. 2009;20( 4):705 -11.
9. Eikelboom JW, Connolly  SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. 
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 
2017;377(14):1319 -30.
10. Patel MR, Mahaffey  KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban 
versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883 -91.
11. Granger CB, Alexander JH, McMurray  JJ, L opes RD, Hy lek EM, Hanna M, et al. 
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 
2011;365(11):981 -92.
12. Kaw D, Malhotra D. Platelet dy sfunction and end-stage renal disease. Semin Dial. 
2006;19(4):317 -22.
13. Palmer SC, Sciancalepore M, Strippoli GF. Trial quality  in nephrology : how are we 
measuring up? Am J Kidney Dis. 2011;58(3):335 -7.
14. Schumacher WA, Luettgen JM, Quan ML , Seiffert DA. Inhibition of factor XIa as a 
new approach to anticoagulation. Arterioscler Thromb Vasc Biol. 2010;30(3):388 -92.
15. Von dem Borne PA, Bajzar L , Meijers JC, Nesheim ME, BN B. Thrombin -mediated 
activation of factor XI results in a thrombin -activatable fibrinolysis inhibitor -
dependent inhibition of fibrinoly sis. J Clin I nvest. 1997;99(10):2323 -7.
16. Bouma BN, Meijers JC. Role of blood coagulation factor XI in downregulation of 
fibrinoly sis. Curr Opin Hematol. 2000;7(5):266- 72.
17. Salomon O, Steinberg DM, Koren -Morag N, Tanne D, Seligsohn U. Reduced 
incidence of ischemic stroke in patients with severe factor XI deficiency . Blood. 
2008;111(8):4113 -7.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  76of 77
18. Cushman M, O'Meara ES, Folsom AR, He ckbert SR. Coagulation factors IX through 
XIII and the risk of future venous thrombosis: the Longitudinal Investigation of 
Thromboembolism Etiology . Blood. 2009;114(14):2878 -83.
19. Preis M, Hirsch J, Kotler A, Zoabi A, Stein N, Rennert G, et al. Factor XI deficiency  
is associated with lower risk for cardiovascular and venous thromboembolism events. 
Blood. 2017;129(9):1210 -5.
20. Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, et al. Factor XI 
antisense oligonucleotide for prevention of veno us thrombosis. N Engl J Med. 
2015;372(3):232 -40.
21. Schaefer M, Buchmueller A, Dittmer F, Strassburger J, Wilmen A. Allosteric 
Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody  
Targeting the Activated Form of Coagulation Factor XI. J Mol Biol. 
2019;431(24):4817 -33.
22. Weitz JI , Bauersachs R, Becker B, Berkowitz SD, Freitas MCS, Lassen MR, et al. 
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients 
Undergoing Knee Arthroplasty : The FOXTROT Randomized Clinical Trial. JAMA. 
2020;323(2):130 -9.
23. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of 
therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493-507.
24. Kaatz S, Ahmad D, Spy ropoulos AC, Schulman S, Subcommittee on Control of 
Anticoagulation. Definition of clinically  relevant non -major bleeding in studies of 
anticoagulants in atrial fibrillation and venous thromboembolic disease in non -surgical 
patients: communication from the SSC of the I STH. J Thromb Haemost. 
2015;13(11):2119 -
26.
25. Hedges SJ, Dehoney  SB, Hooper JS, Am anzadeh J, Busti AJ. Evidence -based 
Treatment Recommendations for Uremic Bleeding. Nat Clin Pract Nephrol. 
2007;3(3):138 -53.
26. Duga S, Salomon O. Congenital factor XI deficiency : an update. Semin Thromb 
Hemost. 2013;39(6):621 -31.
27. Berliner S, Horowitz I, Martinowitz U, Brenner B, Seligsohn U. Dental surgery  in 
patients with severe factor XI deficiency  without plasma replacement. Blood Coagul 
Fibrinoly sis. 1992;3(4):465-8.
28. O'Connell NM, Riddell AF, Pascoe G, Perry DJ, Lee CA. Recombinant factor VIIa to 
prevent surgical bleeding in factor XI deficiency . Haemophilia. 2008;14(4):775-81.
29. Riddell A, Abdul- Kadir R, Pollard D, Tuddenham E, Gomez K. Monitoring low dose 
recombinant factor VIIa therap y in patients with severe factor XI deficiency 
undergoin g surgery . Thromb Haemost. 2011;106(3):521-7.
30. Livnat T, Tamarin I, Mor Y, Winckler H, Horowitz Z, Korianski Y, et al. 
Recombinant activated factor VII and tranexamic acid are haemostatically  effective 
during major surgery  in factor XI -deficient patients with inhibitor antibodies. Thromb 
Haemost. 2009;102(3):487 -92.
31. Ring J, Bey er K, Biedermann T, Bircher A, Duda D, Fischer J, et al. Guideline for 
acute therap y and management of anaph ylaxis: S2 Guideline of the German Society  
for Allergology  and Clini cal Immunology  (DGAKI), the Association of German 
Allergologists (AeDA), the Society  of Pediatric Allergy  and Environmental Medicine 
(GPA), the German Academy  of Allergology  and Environmental Medicine (DAAU), 
the German Professional Association of Pediatri cians (BVKJ), the Austrian Society  
for Allergology  and Immunology  (OGAI), the Swiss Society  for Allergy  and 
Immunology  (SGAI), the German Societ y of Anaesthesiology  and Intensive Care 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 1213790 / 20115
Version 1.0 Page:  77of 77
Medicine (DGAI), the German Societ y of Pharmacology (DGP), the German So ciety  
for Psy chosomatic Medicine (DGPM), the German Working Group of Anaphy laxis 
Training and Education (AGATE) and the patient organization German Allergy  and 
Asthma Association (DAAB). Allergo J I nt. 2014;23(3):96-112.